USRE37438E1 - Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase - Google Patents

Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase Download PDF

Info

Publication number
USRE37438E1
USRE37438E1 US09/304,947 US30494799A USRE37438E US RE37438 E1 USRE37438 E1 US RE37438E1 US 30494799 A US30494799 A US 30494799A US RE37438 E USRE37438 E US RE37438E
Authority
US
United States
Prior art keywords
group
hydrogen
alkyl
acetamidine
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US09/304,947
Inventor
Jeffrey Alan Oplinger
Edward Patrick Garvey
Eric Steven Furfine
Barry George Shearer
Jon Loren Collins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Priority to US09/304,947 priority Critical patent/USRE37438E1/en
Application granted granted Critical
Publication of USRE37438E1 publication Critical patent/USRE37438E1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/30—Isothioureas
    • C07C335/36—Isothioureas having sulfur atoms of isothiourea groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Definitions

  • the present invention relates to acetamidine derivatives, to methods for their manufacture, to pharmaceutical compositions containing them and to their use in therapy, in particular their use as selective inhibitors of nitric oxide synthase.
  • endothelium-derived relaxing factor a labile humoral factor termed endothelium-derived relaxing factor (EDRF).
  • NO nitric oxide
  • NO is the endogenous stimulator of the soluble guanylate cyclase enzyme and is involved in a number of biological actions in addition to endothelium-dependent relaxation including cytotoxicity of phagocytic cells and cell-to-cell communication in the central nervous system (see Moncada et al, Biochemical Pharmacology, 38, 1709-1715 (1989) and Moncada et al, Pharmacological Reviews, 43, 109-142 (1991)). It is now thought that excess NO production may be involved in a number of conditions, particularly conditions which involve systemic hypotension such as septic (toxic) shock and therapy with certain cytokines.
  • L-arginine analogue L-arginine analogue
  • L-NMMA NG-monomethyl-L-arginine
  • the therapeutic use of certain other NO synthase inhibitors apart from L-NMMA for the same purpose has also been proposed in WO 91/04024 and in EP-A-0446699.
  • eNOS Ca++/calmodulin dependent enzyme
  • nNOS Ca++/calmodulin dependent enzyme
  • a Ca++ independent enzyme which is induced after activation of vascular smooth muscle, macrophages, endothelial cells, and a number of other cells by endotoxin and cytokines. Once expressed, this inducible NO synthase synthesises NO for long periods.
  • the NO released by eNOS and nNOS acts as a transduction mechanism underlying several physiological responses.
  • the NO produced by iNOS acts as a cytotoxic molecule for tumour cells and invading micro-organisms. It also appears that the adverse effects of excess NO production, in particular pathological vasodilatation and tissue damage, may result largely from the effects of NO synthesised by iNOS.
  • the NO synthase inhibitors proposed for therapeutic use so far are non-selective in that they inhibit all the NO synthase isoenzymes.
  • Use of such a non-selective NO synthase inhibitor requires that great care is taken in order to avoid the potentially serious consequences of over-inhibition of the eNOS including hypertension and possible thrombosis and tissue damage.
  • L-NMMA for the treatment of septic and/or toxic shock it has been recommended that the patient must be subject to continuous blood pressure monitoring throughout the treatment.
  • NO synthase inhibitors which are selective in the sense that they inhibit iNOS or nNOS to a considerably greater extent than eNOS would be of even greater therapeutic benefit and much easier to use.
  • acetamidine derivatives are inhibitors of NO synthase, and are useful in the treatment of systemic hypotension, and in particular the treatment of septic shock.
  • these compounds show a marked selectivity of one of the isoenzyme with little or no inhibition of the other isoenzymes.
  • the present invention provides an acetamidine derivative of formula (I)
  • R 1 is hydrogen, a C 1-6 hydrocarbyl group optionally substituted by halo, halo, nitro, cyano or a group XR 3 wherein X is oxygen C(O) m wherein m is 1 or 2, S(O) n wherein n is 0, 1 or 2, or a group NR 4 wherein R 4 is hydrogen or C 1-6 alkyl; and R 3 is hydrogen, C 1-6 alkyl, or a group NR 5 R 6 wherein R 5 and R 6 are independently hydrogen or C 1-6 alkyl, provided that R 3 is not NR 5 R 6 when X is oxygen or S(O) n ;
  • R 1a and R 1b are independently selected from hydrogen or halo
  • R 2 is a C 1-14 hydrocarbyl group which may optionally contain one or two heteroatoms, the group R 2 being optionally substituted by one or more groups independently selected from halo; N 3 ; nitro; CF 3 ; ZR 7 wherein Z is oxygen, C(O) m′ wherein m′ is 1 or 2, S(O) n′ wherein n′ is 0, 1 or 2, or a group NR 8 wherein R 8 is hydrogen or C 1-6 alkyl and R 7 is hydrogen, C 1-6 alkyl or a group NR 9 R 8 wherein R 9 and R 10 are independently hydrogen or C 1-6 alkyl; or R 2 is substituted by a group
  • R 11 has a definition the same as for R 1 ;
  • R 1 is a C 1-6 alkyl group and R 2 is a C 1-14 hydrocarbyl substituted by two groups ZR 7 wherein one group ZR 7 is CO 2 H, the other groups ZR 7 is not NH 2 .
  • R 1 is hydrogen, a C 1-6 hydrocarbyl group optionally substituted by halo, halo, nitro, cyano or a group XR 3 wherein X is oxygen, C(O) m wherein m is 1 or 2, S(O) n wherein n is 0, 1 or 2, or a group NR 3 wherein R 4 is hydrogen or C 1-6 alkyl; and R 3 is hydrogen, C 1-6 alkyl, or a group NR 5 R 6 wherein R 5 and R 6 are independently hydrogen or C 1-6 alkyl, provided that R 3 is not NR 5 R 6 when X is oxygen or S(O) n ; and/or
  • R 1a and R 1b are independently selected from hydrogen or halo; and/or
  • R 2 is a C 1-14 hydrocarbyl group which may optionally contain one or two heteroatoms, the group R 2 being optionally substituted by one or two groups which may be the same or different, and are selected from halo; ZR 7 wherein Z is oxygen, C(O) m′ wherein m′ is 1 or 2, S(O) n′ wherein n′ is 0, 1 or 2, or a group NR 8 wherein R 8 is hydrogen or C 1-6 alkyl and R 7 is hydrogen, C 1-6 alkyl or a group NR 9 R 10 wherein R 9 and R 10 are independently hydrogen or C 1-6 alkyl; or R 2 is substituted by a group
  • R 11 has a definition the same as for R 1 ;
  • R 1 is a C 1-6 alkyl group and R 2 is a C 1-14 hydrocarbyl substituted by two groups ZR 7 wherein one group ZR 7 is CO 2 H, the other group ZR 7 is not NH 2 .
  • R 1 is hydrogen, C 1-4 alkyl, halo, nitro, NR 4 R 3 or SR 3 wherein R 3 and R 4 is as hereinbefore defined.
  • R 2 is a C 1-8 hydrocarbyl group optionally containing one or two heteroatoms, each group R 2 being optionally substituted by one group ZR 7 wherein Z and R 7 are as hereinbefore defined, or a group
  • R 12 is fluoro, hydrogen or NH 2 .
  • R 1 is hydrogen, halo (for example fluoro) or NH 2 .
  • R 1a and R 1b are independently hydrogen or fluoro.
  • R 2 is a group
  • One embodiment of the present invention provides a compound of formula (IA)
  • R 1 , R 1a and R 1b are as hereinbefore defined, and R 13 is a C 1-13 hydrocarbyl group which may optionally contain one or two heteroatoms, the group R 13 being optionally substituted by one or two groups which may be the same or different, and are selected from halo, ZR7 or a group
  • a second aspect of the present invention provides a compound of formula (IB)
  • R 1 , R 1a and R 1b are as hereinbefore defined, and R 14 represents one or two substituents on the phenyl ring independently selected from halo, ZR 7 or a group
  • R 14 is a C 1-8 hydrocarbyl group optionally containing one or two heteroatoms, and optionally substituted by one or two groups which may be the same or different, and are selected from halo, ZR 7 or a group
  • the invention provides a compound of the formula IC:
  • R 1 , R 1a and R 1b are as hereinbefore defined;
  • R 15 is a bond or CH 2 ;
  • Y is C 1-6 hydrocarbyl group, phenyl, indanyl or a 5-10 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, N, and S;
  • Y is optionally substituted by one or more groups independently selected from halo, amino, cyano, nitro, hydroxy, C 1-6 hydrocarbyl optionally substituted by hydroxy, C 1-6 alkoxy, C 1-6 thioalkyl, CF 3 , N 3 , a group:
  • n is as hereinbefore defined, C(O) m′ B or S(O) n′ B wherein m′ and n′ are as hereinbefore defined and B is amino or C 1-6 alkyl , a group:
  • n is as hereinbefore defined and D and E are independently hydrogen, hydroxy, amino, C 1-6 alkyl, —CNHCH 3 , —CO 2 t Bu, or a 5-10 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, N or S, a group:
  • n and n′ are as hereinbefore defined and A is phenyl, or a 5- or 6-membered heterocyclic group containing 1 or 2 heteroatoms selected from O, N and S optionally substituted by
  • n is as hereinbefore defined and G is —CO 2 H, —CO 2 C 1-6 alkyl or a 5-10 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, N or S optionally substituted by amino, CNHNH 2 and CH 2 SCNHNH 2 .
  • R 15 is a bond or CH 2 ;
  • Y is C 1-6 hydrocarbyl, phenyl, indanyl or a 5-10 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, N or S;
  • Y is optionally substituted by one or more groups independently selected from halo, amino, cyano, nitro, hydroxy, C 1-6 hydrocarbyl optionally substituted by hydroxy, C 1-6 thioalkyl, a group:
  • n is as hereinbefore defined, C(O) m′ B′ or S(O) n′ B′ wherein m′ and n′ are as hereinbefore defined and B′ is amino or C 1-6 alkyl, a group:
  • n is as hereinbefore defined and D and E are independently hydrogen, hydroxy, amino, C 1-6 alkyl, —CNHCH 3 , —CO 2 t Bu, or a 5-10 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, N or S, a group:
  • n and n′ are as as hereinbefore defined and A is phenyl, or a 5- or 6-membered heterocyclic group containing 1 or 2 heteroatoms selected from O, N and S optionally substituted by
  • n is as hereinbefore defined and G is a 5-10 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, N or S optionally substituted by amino, CNHNH 2 and CH 2 SCNHNH 2 .
  • R 15 is a bond or CH 2 :
  • Y is C 1-6 hydrocarbyl, phenyl, indanyl or a 5-10 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, N or S;
  • Y is optionally substituted by one or more groups independently selected from amino, C 1-6 hydrocarbyl optionally substituted by hydroxy, a group:
  • n as hereinbefore defined, a group:
  • n is as hereinbefore defined and D and E are independently hydrogen, hydroxy, amino, C 1-6 alkyl, —CNHCH 3 , or a 5-10 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, N or S, a group:
  • n and n′ are as hereinbefore defined and A is phenyl, or a 5- or 6-membered heterocyclic group containing 1 or 2 heteroatoms selected from O, N and S optionally substituted by
  • n is as hereinbefore defined and G is a 5-10 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, N or S, CNHNH 2 and CH 2 SCNHNH 2 .
  • a preferred group of compounds within formula (IC) are those where R 15 is a bond. Such compounds are selective inhibitors of the neuronal NOS. Particularly preferred compounds within this sub-group are those where Y is optionally substituted phenyl or a optionally substituted 5-10 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, N or S. Examples of such compounds include:
  • a second preferred group of compounds within formula (IC) are those where R 15 is —CH 2 —.
  • This group of compounds are selective inhibitors of the inducible NOS.
  • Particularly preferred compounds within this subgroup are those where Y is is optionally substituted phenyl, indanyl or a optionally substituted 5-10 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, N or S. Examples of such compounds include:
  • Especially preferred compounds within this group include:
  • Preferred compounds of formula (I) or (IC) include:
  • Especially preferred compounds include N-(3-(aminomethyl)benzyl)acetamidine;
  • hydrocarbyl is meant a group containing only hydrogen and carbon atoms, and may contain double and/or triple bonds and which may be straight, branched, cyclic or aromatic in nature.
  • heteroatom has the meaning known to one skilled in the art and includes nitrogen, oxygen and sulphur atoms.
  • halo is meant fluoro, chloro, bromo, or iodo, and preferably fluoro.
  • the compounds of formula (I) may include a number of asymmetric centres in the molecule depending on the precise meaning of the various groups, and formula (I) is intended to include all possible isomers.
  • the compounds of formula (I) have activity as inhibitors of NO synthase and accordingly a further aspect of the present invention provides a compound of formula (I) for use in medicine.
  • a yet further aspect provides the use of a compound of the invention in the manufacture of a medicament for the treatment of a condition requiring inhibition of NO synthase. More specifically, there is provided the use of a compound of the invention for the manufacture of a medicament for the treatment of a condition where there is an advantage in inhibiting an NO synthase isoenzyme with little or no inhibition of the other isoenzymes.
  • the present invention provides a method of treating a condition requiring inhibition of NO synthase, in particular the inhibition of one NO synthase isoenzyme with little or no inhibition of the other isoenzymes, comprising administering to a mammal in need thereof an effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof.
  • a compound of the invention or salt thereof in the manufacture of a medicament for the treatment of shock states resulting from overproduction of NO by iNOS such as septic shock, or shock caused by fulminant hepatic failure or by therapy with cytokines such as TNF, IL-1 and IL-2 or therapy with cytokine-inducing agents, for example 5, 6-dimethylxanthenone acetic acid.
  • iNOS include a wide range of auto-immune and/or inflammatory diseases, such as those of the joint (e.g. rheumatoid arthritis, osteoarthritis), of the gastrointestinal tract (e.g. ulcerative colitis and other inflammatory bowel diseases, gastritis and mucosal inflammation resulting from infection), of the lung (adult respiratory distress syndrome, asthma), of the heart (myocarditis), of the nervous tissue (e.g. multiple sclerosis), of the pancreas (e.g. diabetes melitus), of the kidney (e.g. glomerulonephritis), of the skin (e.g.
  • inflammatory diseases such as those of the joint (e.g. rheumatoid arthritis, osteoarthritis), of the gastrointestinal tract (e.g. ulcerative colitis and other inflammatory bowel diseases, gastritis and mucosal inflammation resulting from infection), of the lung (adult respiratory distress syndrome, asthma), of the heart (myocarditis), of the nervous tissue
  • a yet further aspect of the present invention provides the use of a compound of formula (I) or salt thereof in the manufacture of a medicament for use in treating the above conditions.
  • Inhibition of neuronal NOS is of benefit in the treatment of diseases of the nervous system due to over production of NO by this isoenzyme, particularly the treatment of cerebral ischemia.
  • Other diseases include CNS trauma, epilepsy, AIDS dementia, chronic neurodegenerative disease and chronic pain, and conditions in which non-adrenergic non-cholinergic nerve may be implicated such as priapism, obesity and hyperphagia.
  • the present invention also provides the use of a compound of formula (I) or a salt thereof in the manufacture of a medicament for use in treating the above conditions.
  • inhibition of NO synthase may be of advantage in preventing the lymphocyte loss associated with HIV infection, and in reducing tumour growth and metastasis.
  • Inhibition of both iNOS and nNOS may be of benefit in the treatment of certain conditions where both isoenzymes play a role, for example CNS conditions such as cerebral ischemia.
  • treatment of a patient is intended to include prophylaxis; the term “mammal” is intended to include a human or an animal.
  • the present invention includes compounds of formula (I) in the form of salts, in particular acid addition salts.
  • Suitable salts include those formed with both organic and inorganic acids.
  • Such acid addition salts will normally be pharmaceutically acceptable although salts of non-pharmaceutically acceptable salts may be of utility in the preparation and purification of the compound in question.
  • preferred salts include those formed from hydrochloric, hydrobromic, sulphuric, citric, tartaric, phosphoric, lactic, pyruvic, acetic, trifluoroacetic, succinic, oxalic, fumaric, maleic, oxaloacetic, methanesulphonic, ethanesulphonic, p-toluenesulphonic, benzenesulphonic and isethionic acids.
  • Salts of compounds of formula (I) can be made by reacting the appropriate compound in the form of the free base with the appropriate acid.
  • the present invention provides a pharmaceutical formulation comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically acceptable carriers therefor and optionally one or more other therapeutic ingredients, for example an antibiotic, and/or a volume replacement liquid.
  • the carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • the formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous and intraarticular), rectal and topical (including dermal, buccal, sublingual and intraocular) administration although the most suitable route may depend upon for example the condition and disorder of the recipient
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof (“active ingredient”) with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary shaping the product into the desired formulation.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
  • the active ingredient may also be presented as a bolus, electuary or paste.
  • a tablet may be made by compression or moulding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent.
  • Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
  • Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example, saline, water-for-injection, immediately prior to use. Alternatively, the formulations may be presented for continuous infusion.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
  • Formulations for rectal administration may be presented as a suppository with the usual carriers such as cocoa butter or polyethylene glycol.
  • Formulations for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerine or sucrose and acacia.
  • Preferred unit dosage formulations are those containing an effective dose, as herein below recited, or an appropriate fraction thereof, of the active ingredient.
  • formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.
  • the compounds of the invention may be administered orally or via injection at a dose of from 0.1 to 250 mg/kg per day.
  • the dose range for adult humans is generally from 5 mg to 17.5 g/day, preferably 5 mg to 2 g/day and most preferably 10 mg to 1 g/day, for example 15 mg to 600 mg/day.
  • Tablets or other forms of presentation provided in discrete units may conveniently contain an amount of compound of the invention which is effective at such dosage or as a multiple of the same, for instance, units containing 5 mg to 500 mg, usually around 10 mg to 200 mg.
  • the compounds of formula (I) are preferably administered orally or by injection (intravenous or subcutaneous).
  • the precise amount of compound administered to a patient will be the responsibility of the attendant physician. However the dose employed will depend on a number of factors, including the age and sex of the patient, the precise disorder being treated, and its severity. Also the route of administration may vary depending on the condition and its severity.
  • Certain compounds of formula (I) are novel, and accordingly a further aspect of the present invention provides a process for the preparation of a compound of formula (I) as hereinbefore defined.
  • R 1 , R 1a and R 1b are as hereinbefore defined followed by deprotection if necessary.
  • the reaction may be carried out in a polar solvent, for example a C 1-4 alkanol such as ethanol at a non-extreme temperature of from ⁇ 20° C. to 100° C. such as 0° C.
  • the 1-benzylthioethaniminium derivative of formula (III) is suitably a halide derivative, preferably a chloride or bromide.
  • Deprotection may be carried out by methods well known to those skilled in the art, for example by methods described in Greene, T. W.; Wuts, P. G. M. (1991) Protective Groups in Organic Synthesis, p 327-330, John Wiley, New York.
  • R 1 , R 1a and R 1b are as hereinbefore defined with benzyl bromide or chloride as described previously (Takido, Y., Itabashi, K. Synthesis 1987, p 817-819).
  • the reaction may be carried out in a solvent such as chloroform at non-extreme temperatures of from 0° C. to 200° C., such as refluxing chloroform.
  • Reagents (a) EtOH, H 2 /Pd/C; (b) NANO 2 , then CuCN; (c) pridine, BnONH 2 .HCl; (d) BH 3 .THF; (e) EtOH, 20° C.; (f) (BOC) 2 —O, MeOH/CH 2 Cl 2 , Et 3 N; (g)HCl, Dioxane.
  • Reagents (a) EtOH, H 2 Pd/C; (b) pyridine, BnONH 2 .HCl; (c) BH 3 .THF; (d) (BOC) 2 —O, MeOH/CH 2 Cl 2 , Et 3 N; (e) EtOH, 20° C.; (f) HBr/AcOH.
  • An additional method for the preparation of compounds of the invention involves the conversion of an azide into an amidine utilising a one-pot method involving triphenylphosphine reduction followed by in situ amidination of the intermediate amine.
  • a further refinement of the method involves the use of polymer-supported triphenylphosphine, the byproduct oxide of which can be readily filtered from the reaction mixture.
  • Examples 11-13 were prepared from the appropriate diamines by methods analogous to example 10:
  • the title compound was prepared as in example 21 from 1.3 g (6.3 mmol) of 3-(N-tert-butoxycarbonyl)-aminoaniline using intermediate C. After removal of EtOH, the residue was diluted with 10 ml of 1,4-dioxane and treated with 2 ml (7.6 mmol, 1.2 equiv) of 3.7M HBr in AcOH. After string 15 min, Et 2 O was added and a solid was collected by filtration.
  • the title compound was prepared from 1.1 g (4.27 mmol) of the above intermediate as in Example 21 using intermediate C. After EtOH removal, 10 ml of 1,4-dioxane was added followed by 0.80 ml of 5.9M HBr in AcOH. After stirring for 30 min Et 2 O was added, and stirring was continued for 2 h.
  • the title compound was prepared from 374 mg (1.25 mmol) of the above oil as in example 47 using intermediate C. After removal of EtOH, 5 ml of 1,4-dioxane was added following by 0.30 ml of 5.9M HBr in AcOH. After stirring for 5 min Et 2 O was added, and stirring was continued overnight.
  • 3-Nitrophenethyl alcohol (2.5 g) was hydrogenated (55 psi, 20° C.) in MeOH (100 ml) in the presence of di-tert-butyl dicarbonate (3.6 g) and 750 mg of 10% palladium on carbon to give 3.7 g (100%) of BOC-protected intermediate (mass spec. 238.0, MH + ). 3.55 g of this alcohol intermediate was converted to azide via the bromide(CBr 4 , PPh 3 , CH 2 Cl 2 , then NaN 3 in DMF) to provide 1.65 g.
  • 6-Nitroindan-1-one (18.1 g, 102 mmol) was dissolved in ethanol (400 ml) and reduced using Pd (5%) on carbon (2.0 g) and 35 psi hydrogen pressure on a Parr apparatus. Filtration on celite followed by evaporation gave 6-aminoindan-1-one (13.7 g, 93 mmol).
  • 6-Aminoindan-1-one (10.0 g, 68 mmol) was treated with pyridine (50 ml) and hydroxylamine-O-benzyl ether.HCl (11.4 g, 71.3 mmol) and heated to 50° C. under N 2 for 40 min. The mixture was evaporated in vacuo and diluted with CH 2 Cl 2 (300 ml). Filtration gave a solid which was washed with a small volume of CH 2 Cl 2 and dried in vacuo to give 6-Amino-1-O-benzyloximinoindane (14.0 g, 48.5 mmol) as the HCl salt.
  • NMR (DMSO) 10.5-9.0 (br s, 3H), 7.5-7.3 (m, 8H), 5.2 (s, 2 H), 3.05 (m, 2H), 2.9 (m, 2H).
  • 6-Amino-1-O-benzyloximinoindane HCl (5.0 g, 17.3 mmol) was treated with 1.0M BH3-THF (86 ml) and warmed under N 2 to 40° C. for 23 hrs. The mixture was evaporated and diluted with CH 2 Cl 2 and quenched by dropwise adition of MeOH. The solvent was evaporated and 1.0N HCl (50 ml) was added and the mixture warmed to 50° C. for 1hr. After cooling, 1.0N NaOH (50 ml) was added and the pH adjusted to 9.5 with additional 1.0N NaOH.
  • 1,6-Diaminoindane ( 0.5 g, 3.4 mmol) was stirred in CH 2 Cl 2 (10 ml) and cooled to 0° C.
  • Di-tert-butyl dicarbonate (0.74 g, 3.4 mmol) in CH 2 Cl 2 (3 ml) was added dropwise over 10 min and the solution stirred overnight.
  • the solution was evaporated in vacuo and diluted with EtOH (20 ml) and cooled to 0° C. Intermediate C was added and the mixture allowed to warm to 20° C. and stirred for 90 min.
  • 4-Nitroindan-1-one was converted to the 1-oximinobenzylether and reduced to 1-amino-4-nitroindane using BH3-THF by the methods described in example 59.
  • 6-Cyanoindan-1-one (prepared using the procedure of Allinger and Jones, JOC 1962, p70. vol 27 for the tetralone analogue) (3.86 g, 24.5 mmol) was converted to the 1-oxime-O-benzyl ether and reduced with BH 3 -THF by the methods described in example 59 to give 1-amino-6-(aminomethyl)indane.
  • the diamine was isolated in 31% yield as the 2 HCl salt by treatment of an ether solution with 4.0N HCl in dioxane.
  • 1-Amino-6-aminomethylindane 2HCl (0.5 g, 2.1 mmol) was stirred in EtOH (20 ml), cooled to 0° C.
  • N-(3-Amino-5-indanyl) methyl)acetamidine (0.10 g, 63%) as the 2 HCl salt.
  • NMR (D 2 O) 7.4-7.3 (m, 3H), 5.2 (m, 1H), 4.1 (s, 2H), 3.1-2.8 (m, 2H), 2.6 (m, 1H), 2.2 (s, 3H, CH 3 ), 2.0 (m, 1H).1H), 3.0-2.8 (m, 1H), 2.6-2.5 (m, 1H), 2.4 (s, 3H, CH 3 ), 2.1-2.0 (m, 1H).
  • 1-Amino-4-(1-imino-2-fluoroethylamino)but-2-ynedihydrobromide was made from 1-azido-4-(butoxycarbonylamino)but-2-yne and S-benzyl-2-fluorothioacetimidate hydrobromide to yield 1-butoxycarbonylamino-4-(1-imino-2-fluoro-ethylamino) but-2-yne hydrobromide as an intermediate.
  • NO synthase inhibition was determined by the following procedure:
  • Amion and chorion were removed from fresh placenta, which was then rinsed with 0.9% NaCl.
  • the tissue was homogenised in a Waring blender in 3 volumes of HEDS buffer (20 mM Hepes pH 7.8, 0.1 mM EDTA, 5mM DTT, 0.2M sucrose) plus 0.1 mM PMSF.
  • the homogenate was filtered through cheesecloth and then centrifuged at 1000 g for 20 min. The supernatant was recentrifuged at 27,500 g for 30 min. Solid ammonium sulphate was added to the supernatant to give 32% saturation.
  • Precipitated protein was pelleted at 25,000 g and then redissolved in a minimal volume of HEDS buffer plus 0.1 mM PMSF, 10 ⁇ g/ml leupeptin and soybean trypsin inhibitor, and 1 ⁇ g/ml pepstatin. The redissolved pellet was centrifuged at 15,000 g for 10 min. To the supernatant was added ⁇ fraction (1/20) ⁇ volume at 2,5′ ADP agarose resin (Sigma), and the slurry was mixed slowly overnight. In the morning, slurry was packed into a column.
  • the resin was sequentially washed with HEDS, 0.5M NaCl in HEDS, HEDS, and then NOS was eluted with 10 mM NADPH in HEDS.
  • the enzyme could be concentrated by ultra filtration and quick frozen and stored at ⁇ 70° C. without loss in activity for at least 3 months.
  • NOS was assayed for the formation of citrulline following the procedure of Schmidt et al (PNAS 88 365-369, 1991) with these modifications: 20 mM Hepes, pH 7.4, 10 ⁇ g/ml calmodulin, 2.5 mM CaC12, 2.5 mM DTT, 125 ⁇ M NADPH, 10 ⁇ M tetrahydrobiopterin, 0.5 mg/ml BSA, and 1 ⁇ M L-[ 14 C]arginine (New England Nuclear). Linearity of NOS-catalysed rate was confirmed prior to kinetic studies that used single time point determination of rate.
  • DLD-1 (ATCC No. CCL 221) were grown at 37° C., 5% CO 2 in RPMI 1640 medium supplemented with L-glutamine, penicillin, streptomycin, and 10% heat-inactivated fetal bovine serum.
  • Cells were grown to confluence and then the following cocktail of cytokines were added: 100 units/ml interferon-gamma, 200 units/ml interleukin-6, 10 ng/ml tumour necrosis factor, and 0.5 ng/ml interleukin-1 ⁇
  • cytokines 100 units/ml interferon-gamma
  • 200 units/ml interleukin-6 200 units/ml interleukin-6
  • 10 ng/ml tumour necrosis factor 10 ng/ml tumour necrosis factor
  • 0.5 ng/ml interleukin-1 ⁇ At 18-24 hr post-induction, cells were harvested by scraping and washed with phosphate-buffered saline. Pelleted cells were
  • citrulline were assayed as described above except that 10 ⁇ M FAD was included and calmodulin and CaCl 2 excluded from the assay mix.
  • Human brain NOS Human brain NOS was prepared using variations of the procedures of Schmidt et al. (PNAS 88 365-369, 1991), Mayer et al. (Fed. Eur. Biochem. Soc. 288 187-191, 1991), and Bredt and Snyder, (PNAS 87 682-685, 1990). Briefly, fresh whole brains (3 with myelinated tissue dissected away, 1050 g) were homogenised in cold buffer A (50 mM HEPES, pH 7.5 (pH at RT) and 0.5 mM EDTA, 10 mM DTT, 3.6 L total volume) with a polytron. The mixture was centrifuged at 13,000 g for 1 hour and the supernatant fluid was removed (about 2050 ml).
  • cold buffer A 50 mM HEPES, pH 7.5 (pH at RT) and 0.5 mM EDTA, 10 mM DTT, 3.6 L total volume
  • the mixture was thawed and passed through at 2′, 5′ ADP-agarose column (0.4 g swelled in buffer A) at 4 ml/min.
  • the column was washed with 100 ml buffer A, 200 ml buffer A with 500 mM NaCl, 100 ml Buffer A, then 30 ml buffer A with 5 mM NADPH.
  • To the enzyme solution was added tetrahydrobiopterin to 10 ⁇ M, FAD and FMN to 1 ⁇ M, and Tween to 0.1%. This solution was concentrated by Centriprep-30 to a volume of approximately 500 ⁇ l. Enzyme activity was determined as described by Schmidt et al. 1991, except that 10 ⁇ M tetrahydrobiopterin was included in the assay.
  • the compounds of the invention exhibit NOS inhibition properties, and certain groups of the compounds exhibit selective inhibition properties against either the inducible or neuronal NOS.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A class of acetamidine derivatives of general formula (I)
Figure USRE037438-20011106-C00001
wherein R1 is hydrogen, C1-6 hydrocarbyl group optionally substituted by halo, halo, nitro, cyano or a group XR3 wherein X is oxygen, C(O)m wherein m is 1 or 2, S(O)n wherein n is 0, 1 or 2, or a group NR4 wherein R4 is hydrogen or C1-6 alkyl; and R3 is hydrogen, C1-6 alkyl, or a group NR5R6 wherein R5 and R6 are independently hydrogen or C1-6 alkyl, provided that R3 is not NR5R6 when X is oxygen or S(O)n; R1a and R1b are independently selected from hydrogen and halo; R2 is a C1-14 hydrocarbyl group which may optionally contain one or two heteroatoms, the group R2 being optionally substituted by one or more groups independently selected from halo; N3; nitro; CF3; ZR7 wherein Z is oxygen, C(O)m′ wherein m′ is 1 or 2, S(O)n′ wherein n′ is 0, 1 or 2, or a group NR8 wherein R8 is hydrogen or C1-6 alkyl and R7 is hydrogen, C1-6 alkyl or a group NR9R10 wherein R9 and R10 are independently hydrogen or C1-6 alkyl; or R2is substituted by a group (a)
Figure USRE037438-20011106-C00002
wherein R11 has a definition the same as for R1;
with the proviso that when R1 is a C1-6 alkyl group and R2 is a C1-14 hydrocarbyl substituted by two groups ZR7 wherein one group ZR7 is CO2H, the other group ZR7 is not NH2;
and salts thereof, methods for the manufacture thereof, and therapies, particularly inhibtion of nitric oxide synthase, is disclosed.

Description

This application is filed pursuant to 35 USC section 371 as a United States National Phase Application of International Application No. PCT/GB95/02978 filed Dec. 20, 1995 which claims priority from GB9425701.1 filed Dec. 20, 1994.
The present invention relates to acetamidine derivatives, to methods for their manufacture, to pharmaceutical compositions containing them and to their use in therapy, in particular their use as selective inhibitors of nitric oxide synthase.
It has been known since the early 1980's that the vascular relaxation brought about by acetylcholine is dependent on the presence of the endothelium and this activity was ascribed to a labile humoral factor termed endothelium-derived relaxing factor (EDRF). The activity of nitric oxide (NO) as a vasodilator has been known for well over 100 years and NO is the active component of amylnitrite, glyceryltrinitrite and other nitrovasodilators. The recent identification of EDRF as NO has coincided with the discovery of a biochemical pathway by which NO is synthesised from the amino acid L-arginine by the enzyme NO synthase.
NO is the endogenous stimulator of the soluble guanylate cyclase enzyme and is involved in a number of biological actions in addition to endothelium-dependent relaxation including cytotoxicity of phagocytic cells and cell-to-cell communication in the central nervous system (see Moncada et al, Biochemical Pharmacology, 38, 1709-1715 (1989) and Moncada et al, Pharmacological Reviews, 43, 109-142 (1991)). It is now thought that excess NO production may be involved in a number of conditions, particularly conditions which involve systemic hypotension such as septic (toxic) shock and therapy with certain cytokines.
The synthesis of NO from L-arginine can be inhibited by the L-arginine analogue, NG-monomethyl-L-arginine (L-NMMA), and the therapeutic use of L-NMMA for the treatment of septic (toxic) shock and other types of systemic hypotension has been proposed (WO 91/04024 and GB-A-2240041). The therapeutic use of certain other NO synthase inhibitors apart from L-NMMA for the same purpose has also been proposed in WO 91/04024 and in EP-A-0446699.
It has recently become apparent that there are at least three isoenzymes of NO synthase (reviewed in Knowles and Moncada, Biochem. J. (1994) 298, 249-258) as follows:
(i) a constitutive, Ca++/calmodulin dependent enzyme (eNOS) which is present in vascular endothelial cells, and that releases NO in response to receptor or physical stimulation.
(ii) a constitutive, Ca++/calmodulin dependent enzyme (nNOS), located in the brain and some peripheral nervous systems, that releases NO in response to receptor or physical stimulation.
(iii) a Ca++ independent enzyme (INOS) which is induced after activation of vascular smooth muscle, macrophages, endothelial cells, and a number of other cells by endotoxin and cytokines. Once expressed, this inducible NO synthase synthesises NO for long periods.
The NO released by eNOS and nNOS acts as a transduction mechanism underlying several physiological responses. The NO produced by iNOS acts as a cytotoxic molecule for tumour cells and invading micro-organisms. It also appears that the adverse effects of excess NO production, in particular pathological vasodilatation and tissue damage, may result largely from the effects of NO synthesised by iNOS.
The NO synthase inhibitors proposed for therapeutic use so far, such as L-NMMA and nitroarginine, are non-selective in that they inhibit all the NO synthase isoenzymes. Use of such a non-selective NO synthase inhibitor requires that great care is taken in order to avoid the potentially serious consequences of over-inhibition of the eNOS including hypertension and possible thrombosis and tissue damage. In particular, in the case of the therapeutic use of L-NMMA for the treatment of septic and/or toxic shock it has been recommended that the patient must be subject to continuous blood pressure monitoring throughout the treatment. Thus, whilst non-selective NO synthase inhibitors have therapeutic utility provided that appropriate precautions are taken, NO synthase inhibitors which are selective in the sense that they inhibit iNOS or nNOS to a considerably greater extent than eNOS would be of even greater therapeutic benefit and much easier to use.
We have found that a class of acetamidine derivatives are inhibitors of NO synthase, and are useful in the treatment of systemic hypotension, and in particular the treatment of septic shock. In addition these compounds show a marked selectivity of one of the isoenzyme with little or no inhibition of the other isoenzymes.
Accordingly, the present invention provides an acetamidine derivative of formula (I)
Figure USRE037438-20011106-C00003
or a salt thereof, wherein
R1 is hydrogen, a C1-6 hydrocarbyl group optionally substituted by halo, halo, nitro, cyano or a group XR3 wherein X is oxygen C(O)m wherein m is 1 or 2, S(O)n wherein n is 0, 1 or 2, or a group NR4 wherein R4 is hydrogen or C1-6 alkyl; and R3 is hydrogen, C1-6 alkyl, or a group NR5R6 wherein R5 and R6 are independently hydrogen or C1-6 alkyl, provided that R3 is not NR5R6 when X is oxygen or S(O)n;
R1a and R1b are independently selected from hydrogen or halo;
R2 is a C1-14 hydrocarbyl group which may optionally contain one or two heteroatoms, the group R2 being optionally substituted by one or more groups independently selected from halo; N3; nitro; CF3; ZR7 wherein Z is oxygen, C(O)m′ wherein m′ is 1 or 2, S(O)n′ wherein n′ is 0, 1 or 2, or a group NR8 wherein R8 is hydrogen or C1-6 alkyl and R7 is hydrogen, C1-6 alkyl or a group NR9R8 wherein R9 and R10 are independently hydrogen or C1-6 alkyl; or R2 is substituted by a group
Figure USRE037438-20011106-C00004
wherein R11 has a definition the same as for R1;
with the proviso that when R1 is a C1-6 alkyl group and R2 is a C1-14 hydrocarbyl substituted by two groups ZR7 wherein one group ZR7 is CO2H, the other groups ZR7 is not NH2.
In preferred embodiments, R1 is hydrogen, a C1-6 hydrocarbyl group optionally substituted by halo, halo, nitro, cyano or a group XR3 wherein X is oxygen, C(O)m wherein m is 1 or 2, S(O)n wherein n is 0, 1 or 2, or a group NR3 wherein R4 is hydrogen or C1-6 alkyl; and R3 is hydrogen, C1-6 alkyl, or a group NR5R6 wherein R5 and R6 are independently hydrogen or C1-6 alkyl, provided that R3 is not NR5R6 when X is oxygen or S(O)n; and/or
R1a and R1b are independently selected from hydrogen or halo; and/or
R2 is a C1-14 hydrocarbyl group which may optionally contain one or two heteroatoms, the group R2 being optionally substituted by one or two groups which may be the same or different, and are selected from halo; ZR7 wherein Z is oxygen, C(O)m′ wherein m′ is 1 or 2, S(O)n′ wherein n′ is 0, 1 or 2, or a group NR8 wherein R8 is hydrogen or C1-6 alkyl and R7 is hydrogen, C1-6 alkyl or a group NR9R10 wherein R9 and R10 are independently hydrogen or C1-6 alkyl; or R2 is substituted by a group
Figure USRE037438-20011106-C00005
wherein R11 has a definition the same as for R1;
with the proviso that when R1 is a C1-6 alkyl group and R2 is a C1-14 hydrocarbyl substituted by two groups ZR7 wherein one group ZR7 is CO2H, the other group ZR7 is not NH2.
Suitably, R1 is hydrogen, C1-4 alkyl, halo, nitro, NR4R3 or SR3 wherein R3 and R4 is as hereinbefore defined.
Suitably, R2 is a C1-8 hydrocarbyl group optionally containing one or two heteroatoms, each group R2 being optionally substituted by one group ZR7 wherein Z and R7 are as hereinbefore defined, or a group
Figure USRE037438-20011106-C00006
wherein R 12 is fluoro, hydrogen or NH2.
Preferably R1 is hydrogen, halo (for example fluoro) or NH2.
Preferably R1a and R1b are independently hydrogen or fluoro.
Preferably R2 is a group
Figure USRE037438-20011106-C00007
wherein p, q and r are independently 0, 1 or 2 and R12 is as hereinbefore defined.
One embodiment of the present invention provides a compound of formula (IA)
Figure USRE037438-20011106-C00008
wherein R1, R1a and R1b are as hereinbefore defined, and R13 is a C1-13 hydrocarbyl group which may optionally contain one or two heteroatoms, the group R13 being optionally substituted by one or two groups which may be the same or different, and are selected from halo, ZR7 or a group
Figure USRE037438-20011106-C00009
wherein Z, R7 and R11 are as hereinbefore defined.
A second aspect of the present invention provides a compound of formula (IB)
Figure USRE037438-20011106-C00010
wherein R1, R1a and R1b are as hereinbefore defined, and R14 represents one or two substituents on the phenyl ring independently selected from halo, ZR7 or a group
Figure USRE037438-20011106-C00011
wherein Z, R7 and R11 are as hereinbefore defined, or R14 is a C1-8 hydrocarbyl group optionally containing one or two heteroatoms, and optionally substituted by one or two groups which may be the same or different, and are selected from halo, ZR7 or a group
Figure USRE037438-20011106-C00012
wherein Z, R7 and R11 are as hereinbefore defined.
In a third aspect the invention provides a compound of the formula IC:
Figure USRE037438-20011106-C00013
wherein R1, R1a and R1b are as hereinbefore defined;
R15 is a bond or CH2; and
Y is C1-6 hydrocarbyl group, phenyl, indanyl or a 5-10 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, N, and S;
wherein Y is optionally substituted by one or more groups independently selected from halo, amino, cyano, nitro, hydroxy, C1-6 hydrocarbyl optionally substituted by hydroxy, C1-6 alkoxy, C1-6 thioalkyl, CF3, N3, a group:
Figure USRE037438-20011106-C00014
 wherein n is as hereinbefore defined, C(O)m′B or S(O) n′B wherein m′ and n′ are as hereinbefore defined and B is amino or C1-6 alkyl , a group:
Figure USRE037438-20011106-C00015
wherein n is as hereinbefore defined and D and E are independently hydrogen, hydroxy, amino, C1-6 alkyl, —CNHCH3, —CO2 tBu, or a 5-10 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, N or S, a group:
—(CH2)n—NH—(CH2)n′A
wherein n and n′ are as hereinbefore defined and A is phenyl, or a 5- or 6-membered heterocyclic group containing 1 or 2 heteroatoms selected from O, N and S optionally substituted by
Figure USRE037438-20011106-C00016
 a group:
—(CH2)n—G
wherein n is as hereinbefore defined and G is —CO2H, —CO2C1-6 alkyl or a 5-10 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, N or S optionally substituted by amino, CNHNH2 and CH2SCNHNH2.
In a preferred embodiment of this aspect of the invention a compound of the formula IC is provided wherein:
R15 is a bond or CH2;
Y is C1-6 hydrocarbyl, phenyl, indanyl or a 5-10 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, N or S;
wherein Y is optionally substituted by one or more groups independently selected from halo, amino, cyano, nitro, hydroxy, C1-6 hydrocarbyl optionally substituted by hydroxy, C1-6 thioalkyl, a group:
Figure USRE037438-20011106-C00017
 wherein n is as hereinbefore defined, C(O)m′B′ or S(O)n′B′ wherein m′ and n′ are as hereinbefore defined and B′ is amino or C1-6 alkyl, a group:
Figure USRE037438-20011106-C00018
wherein n is as hereinbefore defined and D and E are independently hydrogen, hydroxy, amino, C1-6 alkyl, —CNHCH3, —CO2 tBu, or a 5-10 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, N or S, a group:
—(CH2)n—NH—(CH2)n′—A
wherein n and n′ are as as hereinbefore defined and A is phenyl, or a 5- or 6-membered heterocyclic group containing 1 or 2 heteroatoms selected from O, N and S optionally substituted by
Figure USRE037438-20011106-C00019
 a group:
—(CH2)n—G
wherein n is as hereinbefore defined and G is a 5-10 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, N or S optionally substituted by amino, CNHNH2 and CH2SCNHNH2.
In a particularly preferred embodiment of this aspect of the invention the invention provides a compound of the formula IC wherein:
R15 is a bond or CH2:
Y is C1-6 hydrocarbyl, phenyl, indanyl or a 5-10 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, N or S;
wherein Y is optionally substituted by one or more groups independently selected from amino, C1-6 hydrocarbyl optionally substituted by hydroxy, a group:
Figure USRE037438-20011106-C00020
wherein n is as hereinbefore defined, a group:
Figure USRE037438-20011106-C00021
 wherein n is as hereinbefore defined and D and E are independently hydrogen, hydroxy, amino, C1-6 alkyl, —CNHCH3, or a 5-10 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, N or S, a group:
—(CH2)n—NH—(CH2)n′—A
wherein n and n′ are as hereinbefore defined and A is phenyl, or a 5- or 6-membered heterocyclic group containing 1 or 2 heteroatoms selected from O, N and S optionally substituted by
Figure USRE037438-20011106-C00022
 a group:
—(CH2)n—G
wherein n is as hereinbefore defined and G is a 5-10 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, N or S, CNHNH2 and CH2SCNHNH2.
A preferred group of compounds within formula (IC) are those where R15 is a bond. Such compounds are selective inhibitors of the neuronal NOS. Particularly preferred compounds within this sub-group are those where Y is optionally substituted phenyl or a optionally substituted 5-10 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, N or S. Examples of such compounds include:
N-(3-(Hydroxymethyl)phenyl)Acetamidine;
N-(3-(Aminomethyl)phenyl)acetamidine;
N-(3-(( 1,2,3,4-tetrahydroisoquinol-2-yl)methyl)phenyl)-acetamidine;
N-(3-((Methylamino)methyl)phenyl)acetamidine;
N-(Dimethylamino)methyl)phenyl)acetamidine;
N-(3-Morpholinomethyl)phenyl)acetamidine;
N-(3-(Aminomethyl)phenyl)-2-fluoroacetamidine;
N-(3-(2-Aminoethyl)phenyl)acetamidine; and
N-(1,2,3,4-Tetrahydroisoquinolin-7-yl)acetamidine;
and salts thereof.
A second preferred group of compounds within formula (IC) are those where R15 is —CH2—. This group of compounds are selective inhibitors of the inducible NOS. Particularly preferred compounds within this subgroup are those where Y is is optionally substituted phenyl, indanyl or a optionally substituted 5-10 membered heterocyclic group containing 1 or 2 heteroatoms independently selected from O, N or S. Examples of such compounds include:
N-(3-(aminomethyl)benzyl)acetamidine;
N-(4(aminomethyl)benzyl)acetamidine;
N-(3-(Aminomethyl)benzyl)-2-fluoroacetamidine;
N-(3-(Aminomethyl)benzyl)-2-aminoacetamidine;
N-[[6-(Aminomethyl)-2-pyridyl]methyl]acetamidine;
N-(3-(Aminomethyl)benzyl)-2,2,2-trifluoroacetamidine;
N-((1H-Indazol-6-yl)methyl)acetamidine; and
N-(3-Amino-5-indanyl)methyl)acetamidine;
and salts thereof.
Especially preferred compounds within this group include:
N-(3-(aminomethyl)benzyl)acetamidine;
N-(4-(aminomethyl)benzyl)acetamidine;
N-(3-(Aminomethyl)benzyl)-2-fluoroacetamidine;
N-(3-(Aminomethyl)benzyl)-2-aminoacetamidine;
N-[[6-(Aminomethyl)-2-pyridyl]methyl]acetamidine;
N-((1H-Indazol-6-yl)methyl)acetamidine; and
N-(3-Amino-5-indanyl)methyl)acetamidine;
and salts thereof.
Preferred compounds of formula (I) or (IC) include:
N-(3-(aminomethyl)benzyl)acetamidine;
N-(3-(aminomethyl)benzyl)-2-fluoroacetamidine;
N-(4-(aminomethyl)benzyl)acetamidine;
N-(4-aminobutyl)acetamidine;
N-(5-aminopentyl)acetamidine;
N-(6-aminohexyl)acetamidine;
N-(7-aminoheptyl)acetamidine;
N,N′-(1,3-phenylenebis (methylene))bis(acetamidine);
N,N′-(1,4-phenylenebis (methylene))bis(acetamidine);
N,N′-(1,3-phenylene (diethylene))bis(acetamidine);
N,N′-(1,4-phenylene (diethylene))bis(acetamidine);
N-(3-(aminomethyl)benzyl)-2-methoxyacetamidine;
2-Amino-N-(3-aminomethyl)benzyl)acetamidine;
N-(3-(hydroxymethyl)phenyl)acetamidine;
N-(3-(aminomethylphenyl)acetamidine;
N-(3-(Aminomethyl)phenyl)acetamidine;
N-(3-(Aminomethyl)phenyl)-2-fluoroacetamidine; and
N-(3-Amino-5-indanyl)methyl)acetamidine
and salts thereof.
Especially preferred compounds include N-(3-(aminomethyl)benzyl)acetamidine;
N-(3-(aminomethyl)benzyl)-2-fluoroacetamidine;
N-(3-(Aminomethyl)phenyl)acetamidine;
N-(3-(Aminomethyl)phenyl)-2-fluoroacetamidine; and
N-((3-Amino-5-indanyl)methyl)acetamidine
and salts thereof.
By the term “hydrocarbyl” is meant a group containing only hydrogen and carbon atoms, and may contain double and/or triple bonds and which may be straight, branched, cyclic or aromatic in nature.
The term “heteroatom” has the meaning known to one skilled in the art and includes nitrogen, oxygen and sulphur atoms.
By the term “halo” is meant fluoro, chloro, bromo, or iodo, and preferably fluoro.
The compounds of formula (I) may include a number of asymmetric centres in the molecule depending on the precise meaning of the various groups, and formula (I) is intended to include all possible isomers.
As hereinbefore mentioned, the compounds of formula (I) have activity as inhibitors of NO synthase and accordingly a further aspect of the present invention provides a compound of formula (I) for use in medicine.
A yet further aspect provides the use of a compound of the invention in the manufacture of a medicament for the treatment of a condition requiring inhibition of NO synthase. More specifically, there is provided the use of a compound of the invention for the manufacture of a medicament for the treatment of a condition where there is an advantage in inhibiting an NO synthase isoenzyme with little or no inhibition of the other isoenzymes.
In another aspect, the present invention provides a method of treating a condition requiring inhibition of NO synthase, in particular the inhibition of one NO synthase isoenzyme with little or no inhibition of the other isoenzymes, comprising administering to a mammal in need thereof an effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof.
In a further aspect, there is provided the use of a compound of the invention or salt thereof in the manufacture of a medicament for the treatment of shock states resulting from overproduction of NO by iNOS such as septic shock, or shock caused by fulminant hepatic failure or by therapy with cytokines such as TNF, IL-1 and IL-2 or therapy with cytokine-inducing agents, for example 5, 6-dimethylxanthenone acetic acid.
Other conditions where there is an advantage in selectively inhibiting iNOS include a wide range of auto-immune and/or inflammatory diseases, such as those of the joint (e.g. rheumatoid arthritis, osteoarthritis), of the gastrointestinal tract (e.g. ulcerative colitis and other inflammatory bowel diseases, gastritis and mucosal inflammation resulting from infection), of the lung (adult respiratory distress syndrome, asthma), of the heart (myocarditis), of the nervous tissue (e.g. multiple sclerosis), of the pancreas (e.g. diabetes melitus), of the kidney (e.g. glomerulonephritis), of the skin (e.g. dermatitis, psoriasis, urticaria) as well as of transplanted organs (rejection) and multi-organ diseases (e.g. systemic lupus erythematosis). Furthermore there is evidence for overproduction of NO by iNOS in atherosclerosis. Therefore, a yet further aspect of the present invention provides the use of a compound of formula (I) or salt thereof in the manufacture of a medicament for use in treating the above conditions.
Inhibition of neuronal NOS is of benefit in the treatment of diseases of the nervous system due to over production of NO by this isoenzyme, particularly the treatment of cerebral ischemia. Other diseases include CNS trauma, epilepsy, AIDS dementia, chronic neurodegenerative disease and chronic pain, and conditions in which non-adrenergic non-cholinergic nerve may be implicated such as priapism, obesity and hyperphagia. Accordingly the present invention also provides the use of a compound of formula (I) or a salt thereof in the manufacture of a medicament for use in treating the above conditions.
Furthermore inhibition of NO synthase may be of advantage in preventing the lymphocyte loss associated with HIV infection, and in reducing tumour growth and metastasis.
Inhibition of both iNOS and nNOS may be of benefit in the treatment of certain conditions where both isoenzymes play a role, for example CNS conditions such as cerebral ischemia.
As used herein, reference to “treatment” of a patient is intended to include prophylaxis; the term “mammal” is intended to include a human or an animal.
The present invention includes compounds of formula (I) in the form of salts, in particular acid addition salts. Suitable salts include those formed with both organic and inorganic acids. Such acid addition salts will normally be pharmaceutically acceptable although salts of non-pharmaceutically acceptable salts may be of utility in the preparation and purification of the compound in question. Thus, preferred salts include those formed from hydrochloric, hydrobromic, sulphuric, citric, tartaric, phosphoric, lactic, pyruvic, acetic, trifluoroacetic, succinic, oxalic, fumaric, maleic, oxaloacetic, methanesulphonic, ethanesulphonic, p-toluenesulphonic, benzenesulphonic and isethionic acids. Salts of compounds of formula (I) can be made by reacting the appropriate compound in the form of the free base with the appropriate acid.
Whilst it may be possible for the compounds of the present invention to be administered as the raw chemical, it is preferable to present them as a pharmaceutical formulation. According to a further aspect, the present invention provides a pharmaceutical formulation comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, together with one or more pharmaceutically acceptable carriers therefor and optionally one or more other therapeutic ingredients, for example an antibiotic, and/or a volume replacement liquid. The carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
The formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous and intraarticular), rectal and topical (including dermal, buccal, sublingual and intraocular) administration although the most suitable route may depend upon for example the condition and disorder of the recipient The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof (“active ingredient”) with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary shaping the product into the desired formulation.
Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.
A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example, saline, water-for-injection, immediately prior to use. Alternatively, the formulations may be presented for continuous infusion.
Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
Formulations for rectal administration may be presented as a suppository with the usual carriers such as cocoa butter or polyethylene glycol.
Formulations for topical administration in the mouth, for example buccally or sublingually, include lozenges comprising the active ingredient in a flavoured basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerine or sucrose and acacia.
Preferred unit dosage formulations are those containing an effective dose, as herein below recited, or an appropriate fraction thereof, of the active ingredient.
It should be understood that in addition to the ingredients particularly mentioned above, the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.
For each of the aforementioned conditions, the compounds of the invention may be administered orally or via injection at a dose of from 0.1 to 250 mg/kg per day. The dose range for adult humans is generally from 5 mg to 17.5 g/day, preferably 5 mg to 2 g/day and most preferably 10 mg to 1 g/day, for example 15 mg to 600 mg/day. Tablets or other forms of presentation provided in discrete units may conveniently contain an amount of compound of the invention which is effective at such dosage or as a multiple of the same, for instance, units containing 5 mg to 500 mg, usually around 10 mg to 200 mg.
The compounds of formula (I) are preferably administered orally or by injection (intravenous or subcutaneous). The precise amount of compound administered to a patient will be the responsibility of the attendant physician. However the dose employed will depend on a number of factors, including the age and sex of the patient, the precise disorder being treated, and its severity. Also the route of administration may vary depending on the condition and its severity. Certain compounds of formula (I) are novel, and accordingly a further aspect of the present invention provides a process for the preparation of a compound of formula (I) as hereinbefore defined.
Thus, compounds of formula (I) or protected derivatives thereof may be prepared by the reaction of an amine of formula (II)
H2N—R2
or a protected derivative thereof wherein R2 is as hereinbefore defined, with a 1-benzylthioethaniminium derivative of formula (III)
Figure USRE037438-20011106-C00023
wherein R1, R1a and R1b are as hereinbefore defined followed by deprotection if necessary. The reaction may be carried out in a polar solvent, for example a C1-4 alkanol such as ethanol at a non-extreme temperature of from −20° C. to 100° C. such as 0° C. The 1-benzylthioethaniminium derivative of formula (III) is suitably a halide derivative, preferably a chloride or bromide. Deprotection may be carried out by methods well known to those skilled in the art, for example by methods described in Greene, T. W.; Wuts, P. G. M. (1991) Protective Groups in Organic Synthesis, p 327-330, John Wiley, New York.
Compounds of formula (III) may be prepared by the S-alkylation of thioamide compounds of formula (IV)
Figure USRE037438-20011106-C00024
wherein R1, R1aand R1b are as hereinbefore defined with benzyl bromide or chloride as described previously (Takido, Y., Itabashi, K. Synthesis 1987, p 817-819). The reaction may be carried out in a solvent such as chloroform at non-extreme temperatures of from 0° C. to 200° C., such as refluxing chloroform.
Compounds of formula (II) and (IV) are commercially available or may be prepared by methods known to a person skilled in the art.
Where Y is an indanyl group, the following synthetic schemes can be used for the preparation of such compounds:
Figure USRE037438-20011106-C00025
Reagents: (a) EtOH, H2/Pd/C; (b) NANO2, then CuCN; (c) pridine, BnONH2.HCl; (d) BH3.THF; (e) EtOH, 20° C.; (f) (BOC)2—O, MeOH/CH2Cl2, Et3N; (g)HCl, Dioxane.
Figure USRE037438-20011106-C00026
Reagents: (a) EtOH, H2Pd/C; (b) pyridine, BnONH2.HCl; (c) BH3.THF; (d) (BOC)2—O, MeOH/CH2Cl2, Et3N; (e) EtOH, 20° C.; (f) HBr/AcOH.
An additional method for the preparation of compounds of the invention involves the conversion of an azide into an amidine utilising a one-pot method involving triphenylphosphine reduction followed by in situ amidination of the intermediate amine. A further refinement of the method involves the use of polymer-supported triphenylphosphine, the byproduct oxide of which can be readily filtered from the reaction mixture.
Preferred features of each aspect of the invention are as for each other aspect, mutatis mutandis.
THE PRESENT INVENTION WILL NOW BE DESCRIBED BY WAY OF EXAMPLE ONLY: INTERMEDIATE A
Preparation of S-Benzylthioacetimidate Hydrochloride (Takido, Y.; Itabashi, K. Synthesis 1987, p 817-819)
A solution of thioacetamide (60.0 g) and 91.9 ml benzyl chloride in 600 ml chloroform was stirred at reflux for 14 h. Upon cooling to 0° C., the white solids were collected via filtration and dried in vacuo to yield 101 g of a white solid. Dilution of the filtrate with 400 ml Et2O and filtration provided an additional 46 g of a pale yellow solid. 1H NMR (300 MHz, DMSO) δ 7.5-7.3 (m, 5H), 4.66 (s, 2H), 2.67 (s,3H).
The following intermediates were prepared by an analogous method:
B S-Benzylthioacetirndate Hydrobromide: from thioacetamide and benzyl bromide. 1H NMR (200 MHz, DMSO) δ 2.65 (3H, s), 4.63 (2H, s), 7.51-7.31 (5H, m).
C S-(2-Naphthylmethyl)thioacetimidate Hydrobromide: from thioacetamide and 2-(bromomethyl)naphthalene. 1H NMR (200 MHz, DMSO) δ 11.9 (br s, 1H), 8.04-7.92 (m, 4H), 7.6-7.55 (m, 3H), 4.8 (s, 2H), 2.68 (s,3H).
D S-Benzyl-2-fluorothioacetimidate Hydrobromide: from fluorothioacetamide and benzyl bromide. 1H NMR (300 MHz, DMSO) δ 7.5-7.3 (m, 5H), 4.66 (s, 2H), 2.67 (s,3H).
E S-(2-Naphthylmethyl)-2-fluorothioacetimidate Hydrobromide: from fluorothioacetamide and 2-(bromomethyl) naphthalene. 1H NMR (200 MHz, DMSO) δ 7.91-7.82 (m, 4H), 7.65-7.48 (m, 3H), 4.73 (d, J=47.2 Hz, 2H), 3.9 (s,3H).
F S-(2-Naphthylmethyl)-2,2-difluorothioacetimidateHydrobromide: from difluorotdioacetamide and 2-(bromomethyl)naphthalene. (Crude)
G S-Benzyl-2-methoxythioacetimidate Hydrobromide: from 2-methoxy-thioacetamide and benzyl bromide. 1H NMR (200 MHz, DMSO) δ 3.42 (3H,s), 4.61 (2H,s), 4.67 (2H, s), 7.44 (5H, m).
H S-(2-Naphthylmethyl)-2-(thiomethyl)thioacetimidate Hydrobromide: from 2-(thiomethyl)thioacetamide and 2-(bromomethyl)naphthalene. 1H NMR (200MHz, DMSO; D2O) δ 2.09 (3H, s), 3.89 (2H,s), 4.67 (2H, s), 7.91-7.44 (7H, m).
I S-Benzyl-2-tertbutylcarbamoylthioacetimidate Hydrobromide: from 2-(tert-butylcarbamoyl)thioacetamide and benzyl bromide. 1H NMR (200 MHz,DMSO) δ 1.40 (9H, s), 4.27 (2H, d), 4.56 (2H, s), 7.42 (5H, m), 7.79 (1H, t).
J S-Benzylthiopropionimidate Hydrobromide: from benzyl bromide and thiopropionamide. 1H NMR (400 MHz, DMSO) δ 7.46-7.32 (m, 5H), 4.59 (s,2H), 2.83 (d, J=7.5 Hz, 2H), 1.21 (t, J=7.5 Hz, 3H).
EXAMPLE 1 Preparation of N-(3-aminomethyl)benzyl) acetamidine
Preparation of Intermediate tert-butyl-N-(3-(aminomethyl) benzyl)carbamate
10 g (73.42 mmol) of m-xylenediamine was added to 5.1 ml (36.71 mmol) of triethylamine and 200 ml of anhydrous methanol. To this solution at 0° C. was added dropwise over 60 minutes a solution of 8.0 g (36.71 mmol) of di-tert-butyldicarbonate in 60 mL of tetrahyrofuran (anhydrous). The solution was stirred an additional two hours at 0° C., filtered, and concentrated to dryness. The crude material was purified by silica gel chromatography (230-400 mesh silica gel, 250 g). The column was initially eluted with 20% methanol in methylene chloride, then methylene chloride. The crude product was then loaded onto the column and eluted with methanol/ methylene chloride/ ammonium hydroxide ( 5/95/0.5 to 15/85/0.5). Product fractions were concentrated to yield 5.28 g (30%) of a thick, viscous yellow oil. TLC: 10% methanol in methylene chloride (0.5% ammonium hydroxide) on silica gel, Rf=0.7. Mass Spectrum (CI) 237.1 (MH+, 100%), 1H NMR (200 MHz, CDCl3) δ 7.35-7.15 (m, 4H), 4.9 (br. s, 1H), 4.3 (m, 2H), 3.85 (m, 2H), 1.6 (s, 3H).
Amidine Synthesis: Preparation of Intermediate tert-butyl N-(3-((acetimidoyl)aminomethyl)benzyl)-carbamate
To a solution of 2.6 g (11.0 mmol) tert-butyl N-(3-(aminomethyl) benzyl carbamate in 25 ml of absolute ethanol at 0° C. was added 2.22 g (11.0 mmol) of intermediate A. The solution was stirred for three hours and concentrated to dryness. The residue was partitioned between ether (100 ml) and water (100 ml). The aqueous was extracted with ether (50 ml) and freeze-dried to yield 3.28 g (95%) of white solid carbamate hydrochloride as product. 1H NMR (200 MHz, DMSO) δ 7.4-7.3 (m, 1H), 7.24-7.16 (m, 3H), 4.46 (s, 2H), 4.13 (s, 2H), 2.21 (s, 3H), 1.4 (s, 9H). Mass Spectrum (CI) 278.1 (MH+, 100%).
Deprotection of Intermediate tert-butyl N-(3-((Acetimidoyl) aminomethyl)benzyl)-carbamate
Solid tert-butyl N-(3-((acetimidoyl)aminomethyl)benzyl) carbamate (3.0 g, 9.6 mmol) was suspended into 150 ml anhydrous dioxane. 4N Hydrochloric acid in dioxane solution (20 ml) was added at 20° C. The mixture was stirred for 24 hours at 20° C. After diluting with 200 ml ether, the white solids were collected by filtration and dried under vacuum at 100° C. to yield 2.34 g (98%) of N-(3-(aminomethyl)benzyl)-acetamidine. 1H NMR (200 MHz, D2O) δ 7.52-7.35 (m, 4H), 4.49 (s, 2H), 4.16 (s, 2H), 2.25 (s, 3H). Mass Spectrum (CI) 177.9 (MH+, 100%).
EXAMPLE 2 Preparation of N-(3-(Aminomethyl)benzyl)-2-fluoroacetamidine
To a solution of 14 g (59.24 mmol) tert-butyl N-(3-(aminomethyl) benzyl)carbamate in 100 ml ethanol at 0° C. was added 18.8 g (71.1 mmol) of intermediate B. The solution was concentrated after 14 h to a thick oil, stirred vigorously, and 200 ml of ether was added. The residue that separates was washed several times with ether. The resulting solid was stirred in 250 ml of acetic acid and 25 ml of 30% HBr in acetic acid solution. After stirring 30 minutes. 500 ml of ether was added and the solids were collected by filtration and dried to yield 21.55 g (100%) of N-(3-(Aminomethyl) benzyl)-2-fluoroacetamidine as a white solid. A 2.0 g sample was recrystallized from MeOH/EtOAc to yield 1.43 g of a white solid. Mass spectrum (CI) 196.0 (MH+, 76%). 1H NMR (200 MHz, DMSO) δ 7.52-7.38 (m, 4H), 5.42 (d, J=45.3 Hz, 2H), 4.6 (s, 2H), 4.07 (s, 2H).
EXAMPLE 3 Preparation of N-(4-(Aminomethyl)benzyl) acetamidine
Prepared from tert-butyl N-(4-(aminomethyl)benzyl carbamate and intermediate A by the method of example 1 except that the crude deprotection product was freeze-dried from 25 ml water. Mass spectrum (CI) 178 (MH+, 100%). 1H NMR (200 MHz, D2O) δ 7.5-7.35 (m, 4H), 4.5 (s, 2H), 4.15 (s, 2H), 2.15 (s, 3H).
EXAMPLE 4 Preparation of N-(3-(Aminomethyl)benzyl)-2-methoxyacetamidine
The intermediate tert-butyl N-(3-((2-methoxyacetimidoyl) aminomethyl)benzyl)carbamate (360 mg) prepared from tert-butyl N-(3-(aminomethyl)benzyl carbamate and intermediate G analogous to example 1 was deprotected in trifluoroacetic acid at 20° C. for 16 h. The crude product was purified by C18 reverse phase chromatography eluting with water (0.1% trifluoroacetic acid) to yield 150 mg of N-(3-(Aminomethyl)benzyl)-2-methoxyacetamidine as a yellowed, viscous oil (freeze-dried). Mass spectrum (CI) 208.0 (MH+, 100%). 1H NMR (200 MHz, D2O) δ 7.5-7.3 (m, 4H), 4.57 (s, 2H), 4.37 (s, 2H), 4.15 (s, 2H), 3.44 (s, 3H).
EXAMPLE 5 Preparation of N-(3-(Aminomethyl)benzyl)-2-aminoacetamidine
Prepared from 430 mg of tert-butyl N-(3-(aminomethyl) benzyl carbamate and intermediate I analogous to example 4. The freeze-dried fractions left 640 mg of a yellowed viscous oil. Mass spectrum (CI) 193.1 (MH+, 100%). Capillary electrophoresis produced a single peak.
EXAMPLE 6 Preparation of N-(4-Aminobutyl)acetamidine
Prepared from 0.98 g (5.23 mmol) N-Boc-1,4-diaminobutane and intermediate B analagous to example 1. The product residue was purified by preparative reverse phase (C18) chromatography eluting with a methanol/water/trifluoroacetic acid gradient (5/95/0.1 to 90/10/0.1) to yield 0.76 g of pale yellow N-(4-aminobutyl)acetamidine. Capillary electrophoresis gave a single peak (50 mm×40 cm fused silica capillary, 5.5 minutes). Mass spectrum (CI) 130.0 (MH+, 95%). 1H NMR (300 MHz, D2O) δ 3.15 (m, 2H), 2.89 (m, 2H), 2.08 (s, 3H), 1.62-1.55 (m, 4H).
EXAMPLE 7 Preparation of N-(5-Aminopentyl)acetamidine
Prepared from 0.97 g (4.8 mmol) N-Boc-1,5-diaminopentane analogous to example 6. Capillary electrophoresis gave a single peak (50 mm×40 cm fused silica capillary, 5.9 minutes). Mass spectrum (CI) 144.0 (MH+, 100%). 1H NMR (300 MHz, D2O) δ 3.12 (m, 2H), 2.85 (m, 2H), 2.08 (s, 3H), 1.6-1.5 (m, 4H), 1.35-1.25 (m, 2H).
EXAMPLE 8 Preparation of N-(6-Aminohexyl)acetamidine
To a 0° C. stirred solution of 1.0 g (4.62 mmol) of N-Boc-1,6-diaminohexane in 30 ml ethanol was added 0.86 g (4.62 mmol) of intermediate B. After two hours the solution was concentrated, diluted with water (50 ml), and extracted with ether twice. The aqueous phase was freeze-dried to yield 0.9 g of white sticky solid tert-butyl N-(6-((acetimidoyl) amino)hexyl)carbamate intermediate. A suspension of the carbamate above (0.88 g, 3 mmol) in 15 ml dioxane and 7.5 ml trifluoroactic acid was treated with 10 ml (40 mmol) of 4N hydrochloric acid in dioxane solution with stirring overnight. The mixture was diluted with ether (50 ml) and the solids were isolated by filtration to provide 0.7 g N-(6-aminohexyl)acetamidine as a white solid (66% yield from N-Boc-1,6-diaminohexane). M.P.=163°-164° C. Mass spectrum (CI) 158.1 (MH+, 100%).
EXAMPLE 9 Preparation of N-(7-Aminoheptyl)acetamidine
Prepared from N-Boc-1,7-diaminohexane (1.0 g, 4.34 mmol) by the method of example 8 to yield 0.76 g of the title compound as a white solid. M.P.=165°-168° C. Mass spectrum (CI) 172.1 (MH+, 100%). 1H NMR (300 MHz, D2O) δ 3.16 (t, J=7.0 Hz, 2H), 2.9 (t, J=7.5 Hz, 2H), 2.11 (s, 3H), 1.59-1.5 (m, 4H), 1.28 (br s, 6H).
EXAMPLE 10 Preparation of N,N′-(1,3-Phenylenebis(methylene)) bis(acetamidine)
To a solution of 1.0 g (7.34 mmol) m-xylenediamine in 75 ml ethanol at 0° C. was added 3.7 g (15.0 mmol) of solid intermediate B. The solution was stirred at 0° C. for two hours and concentrated. The residue was taken into 50 ml of water and extracted twice with ether (2×50 ml). The aqueous solution was freeze-dried to provide a quantitative yield of N,N′-(1,3-phenylenebis(methylene))bis(acetamidine) bis-hydrobromide as a white solid (2.81 g). Mass spectrum (CI) 219.0 (MH+, 26%). 1H NMR (300 MHz, D2O) δ 7.3 (m, 1H), 7.2 (m, 3H), 4.35 (s, 4H), 2.15 (s, 6H).
Examples 11-13 were prepared from the appropriate diamines by methods analogous to example 10:
EXAMPLE 11 N,N′-(1,4-Phenylenebis(methylene))bis(acetamidine)
Mass spectrum (FAB) 219.3 (MH+, 100%). 1H NMR (300 MHz, D2O) δ 7.45 (s, 4H), 4.46 (s, 4H), 2.2 (s, 6H).
EXAMPLE 12 N,N′-(1,3-Phenylene(diethylene))bis(acetamidine)
Mass spectrum (FAB) 247.2 (MH+, 100%). 1H NMR (200 MHz, D2O) δ 7.35-7.15 (m, 4H), 3.50 (t, J=6.8 Hz, 4H), 2.9 (t, J=6.9 Hz, 4H), 2.1 (s, 6H).
EXAMPLE 13 N,N′-(1,4-Phenylene(diethylene))bis(acetamidine)
Mass spectrum (CI) 247 (MH+, 25%). 1H NMR (300 MHz, D2O) δ 7.16 (s, 4H), 3.40 (t, J=6.8 Hz, 4H), 2.81 (t, J=6.8 Hz, 4H), 2.04 (s, 6H).
EXAMPLE 14 Preparation of N-(3-(hydroxymethyl)phenyl) acetamidine
Prepared from 1.23 g (10 mmol) 3-aminobenzyl alcohol and 2.22 g (11.0 mmol) of intermediate A by the method of example 1 to provide a white solid (2.0 g, 100% yield). Mass spectrum (CI) 165.0 (MH+, 100%). Capillary zone electrophoresis on a fused silica column (75 microns×40 cm) at pH=2 gave a 7.78 minute retention time, 99.3% purity. 1H NMR (300 MHz, D2O) δ 7.4 (t, J=7.7 Hz, 1H), 7.3 (d, J=7.4 Hz, 1H), 7.18 (s, 1H), 7.13 (d, J=7.9 Hz, 1H), 4.52 (s, 2H), 2.26 (s, 3H).
EXAMPLE 15 Preparation of N-(3-(Aminomethyl)phenyl) acetamidine
To a stirred solution of 2.5 g (13.25 mmol) 3-nitrobenzylamine hydrochloride and 8.5 ml (30 mmol) of triethylamine in 75 ml anhydrous methanol and 25 ml anhydrous tetrahydrofuran was added 3.19 g (14.5 mmol) di-tertbutyl dicarbonate. The solution was filtered after 14 hours, concentrated, and purified by silica gel chromatography to yield 3.3 g (100%) of protected intermediate (silica gel Rf=0.45, 30% ethyl acetate in hexanes). A solution of 3.1 g (12.29 mmol) of this intermediate was hydrogenated for 90 minutes under 50 psi hydrogen in 75 ml methanol in the presence of 1 g 10% palladium on carbon. The mixture was filtered and concentrated to an oil (2.65 g). This oil was taken into 30 ml ethanol (0° C.) and 2.48 g (12.3 mmol) intermediate A was added. After 3 hours, the solution was concentrated, partitioned between 100 ml ether and 40 ml water, and the aqueous phase was washed with ether (100 ml) and freeze-dried to a white solid (3.5 g, 95% yield). Mass spectrum (CI) 264.1 (MH+, 100%). To a suspension of 2.0 g (6.67 mmol) of this solid in 20 mL dioxane was added 30 ml of 4N hydrochloric acid in dioxane solution. The suspension was stirred for two hours, diluted with 150 ml ether, and filtered. The solids recovered were dried under vacuum to yield 1.36 g (86%) of the title compound N-(3-aminomethylphenyl)acetamidine dihydrochloride. Mass spectrum (CI) 164.0 (MH+, 100%). Capillary zone electrophoresis on a fused silica column (75 microns×40 cm) at pH=2.1 gave a 5.06 minute retention time, 97.6% purity. 1H NMR (300MHz, DMSO) δ 7.6-7.5 (m, 3H), 7.3 (m, 1H), 4.03 (s, 2H), 2.36 (s, 3H).
EXAMPLE 16 Preparation of N-[[6-(Aminomethyl)-2-pyridyl] methyl]acetamidine
Prepared from 1.5 g (10.9 mmol) Bis-2,6-(aminomethyl) pyridine ( synthesized by standard methods from 2,6-pyridinedimethanol via bromination with carbon tetrabromide and triphenylphosphine, bis-azide formation with sodium azide in dimethylformamide, and catalytic hydrogenation to the diamine with palladium on carbon) and intermediate B analogous to example 10. The crude product was purified by preparative reverse phase HPLC (C18) eluting with a gradient of methanol/water/trifluoroacetic acid (10/90/0.1 to 90/10/0.1) and freeze-dried to yield N-[[6-(aminomethyl)-2-pyridyl]methyl]acetamidine (clear, colorless, viscous oil, 130 mg). Mass spectrum (CI) 179.0 (MH+, 100%).
EXAMPLE 17 PreparationofN-(2-(5-((acetimidoylamino)methyl)-2-thienyl)ethyl)acetamidine
Prepared from 2-(2-Aminoethyl)-5-(aminomethyl) thiophene and intermediate B analogous to example 10. Mass Spectrum (FAB) 239.1 (MH+). 1H NMR (200 MHz D2O) δ 6.95 (d, J=3.5 Hz, 1H), 6.81 (d, J=3.4 Hz, 1H), 4.58 (s, 2H), 3.52 (t, J=6.6 Hz, 2H), 3.1 (s, 3H), 2.14 (s, 3H).
EXAMPLE 18 Preparation of N-(3-(5-(2-(Acetimidoylamino)ethyl)-2-thienyl)propyl)acetamidine
Prepared from 2-(2-Aminoethyl)-5-(3-aminopropyl) thiophene and intermediate B analogous to example 10. Mass Spectrum (FAB) 267.3 (MH+). 1H NMR (200 MHz D2O) δ 6.75-6.7 (m, 2H), 3.50 (t, J=6.6 Hz, 2H), 3.23 (t, J=6.7 Hz, 2H), 3.07 (t, J=6.6 Hz, 2H), 2.85 (t, J=7.3 Hz, 2H), 2.14 (s, 6H), 2.0-1.9 (m, 2H).
EXAMPLE 19 Preparation of N-(3-(Aminomethyl)benzyl)-2,2-difluoroacetamidine
Prepared from tert-butyl N-(3-(aminomethyl)benzyl) carbamate and intermediate F analogous to example 1. 1H NMR (200 MHz, D2O) δ 4.17 (2H, s), 4.64 (2H, s), 6.70 (1H, t, J=52.5 Hz), 7.47 (4H, m). Mass Spectrum (CI) 214.1 (MH+, 100%).
EXAMPLE 20 Preparation ofN-(3-(Aminomethyl)benzyl)-2,2,2-trifluoroacetamidine
To an excess of freshly condensed trifluoroacetonitrile stirring at −78° C. was added a solution of tert-butyl N-[3-(aminomethyl) benzyl]carbamate (746 mg, 3.16 mmol) in CH3CN (5 ml) dropwise. The mixture froze into a solid white mass. After warming to room temperature, the mixture was warmed gently in a warm water bath to remove excess trifluoroacetonitrile. The mixture was concentrated at reduced pressure and the residue was chromatographed on silica gel eluting with 2:3 ethyl acetate in hexane to provide 897 mg (86%) of a viscous oil. To a stirred solution of the above oil (887 mg, 2.68 mmol) in dioxane (20 ml) was added 30% HBr in acetic acid (3 ml, 15.0 mmol). The resulting suspension was stirred for 6h, poured into ethyl acetate (200 ml) and stirred for 30 minutes. The solid was collected, suspended in hot iPrOH, cooled to rt. recollected and dried in vacuo to afford 731 mg (69%) of N-[3-(aminomethyl)benzyl]-2,2,2-trifluoroacetamidine as a dihydrobromide salt Mp=242°-244° C. 200 MHz 1H NMR (D2O) δ 4.18 (2H, s), 4.67 (2H, s), 7.48 (4H, m).
EXAMPLE 21 Preparation of 3-(2-Fluoroacetimidoylamino) benzamide
A solution of 1.0 g (7.34 mmol) of 3-aminobenzamide in 15 ml of absolute ethanol at room temperature was treated with intermediate D and stirred 24 h. After concentration in vacuo to 5-10 ml, the residue was treated with Et2O and filtered to give 1.69 g of an off-white solid. Recrystallization from MeOH/Et2O provided 1.0 g (50%) of the title compound as a white solid: mp 219°-220° C.; 1H NMR (D2O, 300 MHz) δ 7.70 (d, 1 H, J=7.6 Hz), 7.66 (s, 1 H), 7.56 (t, 1 H, J=7.6 Hz), 7.46 (d, 1 H, J=7.6 Hz), 5.46 (s, 1 H), 5.31 (s, 1 H).
The following compounds (22-43) were prepared in an analogous manner to example 21:
EXAMPLE 22 Preparation of 3-(Acetimidoylamino)benzamide
Prepared from 3-aminobenzamide (1.0 g) and intermediate B (1.63 g). The white solids were filtered and dried to yield 1.55 g of 3-(Acetimidoylamino)benzamide. Mass Spectrum (CI) 178.0 (MH+, 100%).
EXAMPLE 23 Preparation of N-(3-(2-Hydroxyethyl)pheny) acetamidine
Prepared from 3-(2-hydroxyethyl)aniline and intermediate A. Mass Spectrum (CI) 179.0 (MH+, 100%).
EXAMPLE 24 Preparation of N-(3-Fluorophenyl)acetamidine
Prepared from 3-fluoroaniline using intermediate A. Recrystallization from MeOH/Et2O provided 816 mg (48%) of the title compound as a white solid: mp 175°-177° C.; 1H NMR (D2O, 200 MHz) δ 7.52 (m, 1 H), 7.28-7.05 (m, 3 H), 2.37 (s, 3 H).
EXAMPLE 25 Preparation of 3-(Acetimidoylamino)benzamidine
Prepared from 3-amino-benzamidino 2HCl using intermediate A and 1 equivalent of Et3N. Recrystallization from MeOH/Et2O provided 1.48 g (82%) of a white solid: mp 263°-265° C.; 1H NMR (D2O, 300 MHz) δ 7.13 (dt, 1 H, J=7.8, 1.5 Hz), 7.66-7.52 (m, 3 H), 2.29 (s, 3H).
EXAMPLE 26 Preparation of N-(3-Nitrophenyl)acetamidine
Prepared from 3-nitroaniline using intermediate A. Recrystallization from MeOH/Et2O gave 513 mg (35%) of a white solid. The solid was dissolved in CH2Cl2, basified with saturated NaHCO3, and extracted with CH2Cl2. The combined organic layers were dried (Na2SO4), filtered, and concentrated in vacuo. The yellow solid was treated with iPrOH followed by HCl in EtOH. Et2O was added, and resulting white solid was collected to give 310 mg of title compound: mp 226°-228° C.; 1H NMR (D2O, 300 MHz) δ 8.24-8.10 (m, 2 H), 7. 70-7.58 (m, 2 H), 2.31 (s, 3 H).
EXAMPLE 27 Preparation of N-(3-Acetylphenyl)acetamidine
Prepared from 3-aminoacetophenone using intermediate A. Recrystallization from MeOH/Et2O gave 1.16 g (74%) of a white solid. The solid was dissolved in Et2O/saturated NaHCO3, and the aqueous layer was extracted with Et2O. The combined organics were dried (Na2SO4), filtered, and concentrated in vacuo. The residue was treated with Et2O and a small amount of HCl/ethanol. The resulting white solid was collected to give 325 mg of title compound: mp 204°-206° C.; IH NMR (D2O, 300 MHz) δ 7.92 (dt, 1 H, J=7.6, 1.2 Hz), 7.77 (br s, 1 H), 7.55 (t, 1 H, J=7.6 Hz), 7.46 (dt, 1 H, J=7.6, 1.8 Hz), 2.52 (s, 3 H), 2.29 (s, 3 H).
EXAMPLE 28 Preparation of N-(3-Cyanophenyl)acetamidine
Prepared from 3-aminobenzonitrile using intermediate A. Recrystallization from MeOH/Et2O gave 814 mg (50%) of a solid. The solid was dissolved in Et2O/saturated NaHCO3, and the aqueous layer was extracted with Et2O. The combined organics were dried (Na2SO4), filtered, and concentrated in vacuo. The residue was treated with Et2O and a small amount of HCl/ethanol. The resulting white solid was collected to give 576 mg of title compound: mp 228°-230° C.; 1H NMR (D2O, 300 MHz) δ 7.72 (dt, 1 H, J=7.8, 1.5 Hz), 7.64 (br s , 1 H), 7.62-7.49 (m, 2 H), 2.28 (s, 3 H).
EXAMPLE 29 Preparation of N-(3-Bromophenyl)acetamidine
Prepared from 3-bromoaniline using intermediate A. The resulting solid was dissolved in Et2O/Saturated NaHCO3, and the aqueous layer was extracted with Et2O. The combined organics were dried (Na2SO4), filtered, and concentrated in vacuo. The residue was treated with Et2O and a small amount of HCl/ethanol. The resulting white solid was collected to give 776 mg (54%) of title compound: mp 208°-210° C.; 1H NMR (D2O, 300 MHz) δ 7.52 (d, 1 H, J=7.8 Hz), 7.43 (br s, 1 H), 7.31 (t, 1 H, J=7.8 Hz), 7.18 (d, 1 H, J=7.8 Hz), 2.26 (s, 3H).
EXAMPLE 30 Preparation of N-(3-(Methylthio)phenyl)acetamidine
Prepared from 3-(methylmercapto)-aniline using intermediate A. Recrystallization from MeOH/Et2O gave 1.11 g (71%) of a purple solid. The resulting solid was dissolved in Et2O/saturated NaHCO3, and the aqueous layer was extracted with Et2O. The combined organics were dried (Na2SO4), filtered, and concentrated in vacuo. The residue was treated with Et2O and a small amount of HCl/ethanol. The resulting solid was collected to give 778 mg of title compound: mp 134°-135° C.; 1H NMR (D2O, 300 MHz) δ 7.33 (t, 1 H, J=7.8 Hz), 7.23 (d, 1 H, J=7.8 Hz), 7.09 (br s, 1 H), 6.97 (d, 1 H, J=7.8 Hz), 2.36 (s, 3H), 2.25 (s, 3H).
EXAMPLE 31 Preparation of N-(3-(1-Hydroxyethyl)phenyl) acetamidine
Prepared from (+)-3-(1-hydroxyethyl)aniline using intermediate C. Upon stirring overnight, the reaction was filtered, and the filtrate was concentrated in vacuo. The residue was triturated with absolute EtOH/pentane, and the title compound was collected by filtration to give 2.1 g (88%) of an off-white solid: mp 132°-135° C.; 1H NMR (D2O, 300 MHz) δ 7.40 (t, 1 H, J=7.8 Hz), 7.33 (d, 1 H, J=7.8 Hz), 7.19 (s, 1 H), 7.12 (d, 1 H, J=7.8 Hz), 4.80 (q, 1 H, J=6.6 Hz), 2.26 (s, 3 H), 1.32 (d, 3 H, J=6.6 Hz).
EXAMPLE 32 Preparation of N-(3-Acetimidoylamino)benzyl) acetamidine
A solution of 1.2 g (6.36 mmol) of 3-nitrobenzylamineoHCl in 50 ml of EtOH containing 150 mg of 10% palladium on carbon was placed on a Parr hydrogenator under H2 for 1 h. The reaction was filtered through a pad of celite washing with EtOH, and the filtrate was concentrated in vacuo. The residue was dissolved in CH2Cl2 and treated with 1.0N NaOH. The aqueous layer was extracted with CH2Cl2, and the combined organic layers were dried (MgSO4), filtered, and concentrated in vacuo to give 600 mg (77%) of 3-aminobenzyl amine which was used directly in the next reaction. The title compound was prepared as in example 21 from 600 mg of 3-aminobenzylamine using 2 equivalents of intermediate C. Recrystallization from MeOH/Et2O provided 1.46 g (81%) of a white solid: mp 276°-277° C.; 1H NMR (D2O, 300 MHz) δ 7.45 (t, 1 H, J=7.8 Hz), 7.31 (d, 1 H, J=7.8 Hz), 7.25-7.15 (m, 2 H), 4.41 (s, 2 H), 2.28 (s, 3 H), 2.15 (s, 3 H).
EXAMPLE 33 Preparation of N-(3-Acetimidoylamino) benzenesulfonamide
A solution of 1.5 g (7.42 mmol) of 3-nitrobenzenesulfonamide in 50 ml of EtOH containing 150 mg of 10% palladium on carbon was placed on a Parr hydrogenator under H2 for 1 h. The reaction was filtered through a pad of celite washing with EtOH, and the filtrate was concentrated in vacuo to give 1.28 g (100%) of 3-aminobenzenesulfonamide which was used immediately in the next reaction. The tide compound was prepared as in example 21 from 3-aminobenzenesulfonamide using intermediate C. Recrystallization from MeOH/Et2O provided 1.46 g (67%) of title compound as an off-white solid: mp 240°-242° C.; 1H NMR (D2O, 300 MHz) δ 7.86 (d, 1 H, J=8.1 Hz), 7.75 (s, 1 H), 7.63 (t, 1 H, J=8.1 Hz), 7.51 (d, 1 H, J=8.1 Hz), 2.30 (s, 3 H).
EXAMPLE 34 Preparation of N-(3-((1,2,3,4-Tetrahydroisoquinol-2-yl) methyl)phenyl)acetamidine
A solution of 1.0 g (4.63 mmol) of 3-nitrobenzyl bromide in 30 ml of toluene was treated with 1.16 ml (9.26 mmol, 2 equiv) of 1,2,3,4-tetrahydroisoquinoline. After heating at reflux for 1 h followed by cooling to 25° C., the reaction was diluted with EtOAc, washed with 1N NaOH, dried (MgSO4), filtered, and concentrated in vacuo. The residue was filtered through a pad of silica gel eluting with hexanes/Et2O (2:1), and the filtrate was concentrated in vacuo to give 1.21 g (76%) of intermediate. A solution of 1.21 g (3.50 mmol) of the above nitroaromatic in 50 ml of EtOAc was treated with 140 mg of 10% palladium on carbon and placed on a Parr hydrogenator under H2 until gas consumption ceased. The reaction was filtered through a pad of silica gel washing with EtOAc, and the filtrate was concentrated in vacuo to give 1.0 g (89%) of a yellow solid that was used immediately in the next reaction. The title compound was prepared from 1.0 g (3.13 mmol) of the above compound as in example 21 using intermediate C. After removal of EtOH, 10 ml of 1,4-dioxane was added followed by 1.2 ml of 3.7M HBr in AcOH. After stirring for 5 min, the reaction was treated with Et2O and stirred 3 h. An orange solid was collected and recrystallized from EtOH/EtOAc to give 366 mg (27%) of title compound as a brown solid: mp 260°-262° C.; 1H NMR (D2O, 300 MHz) δ 7.64-6.94 (m, 8 H), 4.41 (br s, 2 H), 4.26 (s, 2 H), 3.69 (br s, 1 H), 3.36 (br s, 1 H), 3.06 (br s, 1 H), 2.29 (s, 3 H).
EXAMPLE 35 Preparation of N-(3-(2-Amino-4-thiazolyl)phenyl) acetamidine
To a solution of 5 g (20.5 mmol) of a-bromo-3-nitroacetophenone in 20 ml of acetone at 25° C. was treated with 1.6 g (20.5 mmol, 1 equiv) of thiourea. After stirring overnight, 6.1 g (98%) of a white solid was collected by filtration. A solution of 5.1 g (16.9 mmol) of the above compound in 200 ml of EtOH was treated with 500 mg of 10% palladium on carbon and placed on a Parr hydrogenator under H2 for 2.5 h. The reaction was filtered through a pad of celite washing with EtOH, and the filtrate was concentrated in vacuo. The residue was dissolved in CH2Cl2 and basified with 1N NaOH. The aqueous layer was extracted with CH2Cl2, and the combined organic layers were dried (MgSO4), filtered, and concentrated in vacuo to give 1.78 g (55%) of intermediate which was used directly in the next reaction. The title compound was prepared as in example 21 from 1.03 g (5.38 mmol) of the above compound using intermediate C. After removal of EtOH, the residue was diluted with 10 ml of 1,4-dioxane and acidified with 3.7M HBr in AcOH. After stirring 30 min, Et2O was added and a solid was collected by filtration. The solid was recrystallized from MeOH/Et2O to give 1.09 g (51%) of title compound as a white solid: mp 252°-254° C.; 1H NMR (D2O, 300 MHz) δ 7.62-7.40 (m, 3 H), 7.29 (br d, 1 H, J=7.5 Hz), 6.91 (s, 1 H), 2.29 (s, 3 H).
EXAMPLE 36 Preparation of N-(3-Aminophenyl)acetamidine
A solution of 10 g (72.4 mmol) of 3-nitroaniline in 200 ml of CH2Cl2 at 25° C. was treated sequentially with 10 ml (71.4 mmol) of Et3N, 17.4 g (72.4 mmol) of BOC2O, and a catalytic amount of DMAP. After stirring for 72 h, the reaction was filtered through a pad of silica gel washing with hexanes/EtOAc (1:1), and the filtrate was concentrated in vacuo. Purification by medium pressure silica gel column chromatrography using hexanes/EtOAc (3:1→1:1) provided 4.4 g (26%) of 3-(N-tert-butoxycarbonyl)-nitroaniline which was used directly in the next reaction. A solution of 1.5 g (6.3 mmol) of the nitroaromatic in 50 ml of EtOAc was treated with 150 mg of 10% palladium on carbon and placed on a Parr hydrogenator under H2 for 2 h. The reaction was filtered through a pad of silica gel washing with EtOAc, and the filtrate was concentrated in vacuo to give 1.3 g (100%) of intermediate which was used directly in the next reaction. The title compound was prepared as in example 21 from 1.3 g (6.3 mmol) of 3-(N-tert-butoxycarbonyl)-aminoaniline using intermediate C. After removal of EtOH, the residue was diluted with 10 ml of 1,4-dioxane and treated with 2 ml (7.6 mmol, 1.2 equiv) of 3.7M HBr in AcOH. After string 15 min, Et2O was added and a solid was collected by filtration. The solid was recrystallized from MeOH/EtOAc to give 1.15 g (59%) of title compound as a white solid: mp 288°-289° C.; 1H NMR (D2O, 300 MHz) δ 7.51 (t, 1 H, J=8.1 Hz), 7.33-7.24 (m, 2 H), 7.20 (t, 1 H, J=1.8 Hz), 2.27 (s, 3H).
EXAMPLE 37 Preparation of N-(3-((Methylamino)methyl)phenyl) acetamidine
To a solution of 2.0 g (7.93 mmol) of 3-(N-tert-butoxycarbonyl)-nitrobenzylamine in 32 ml of anhydrous THF at −78° C. was added 6.34 ml (9.51 mmol, 1.2 equiv) of 1.5M LDA in cyclcohexane. After stirring for 25 min, 0.592 ml (9.51 mmol, 1.2 equiv) of MeI was added, and the reaction was immediately warmed to 25° C. and stirred 4 h. The solution was poured into H2O and extracted with Et2O. The combined organic layers were dried (MgSO4), filtered, and concentrated in vacuo. Purification by flash silica gel column chromatography using hexanes/Et2O (2:1) provided 2.1 g (59%) of intermediate 3-(N-methyl-N-tert-butoxycarbonyl) nitrobenzylamine. A solution of 1.25 g (4.7 mmol) of the above nitroaromatic in 50 ml of EtOAc at 25° C. was treated with 140 mg of 10% palladium on carbon and placed on a Parr hydrogenator under H2 for 4 h. The reaction was filtered through a pad of silica gel washing with EtOAc. The filtrate was concentrated in vacuo to give 1.11 g (100%) of intermediate. The title compound was prepared analogous to example 21 from the above aniline intermediate (1.11 g ,4.69 mmol) and intermediate C. After removal of EtOH, 10 ml of 1,4-dioxane was added followed by 1 ml (5.9 mmol) of 5.9M HBr/AcOH. After stirring 5 min, Et2O was added and stirring was continued for 2 h. Filtration provided a solid that was recrystallized from MeOH/EtOAc to give 950 mg (59%) of title compound as a white solid: mp 222°-223° C.; 1H NMR (D2O, 300 MHz) δ 7.54-7.24 (m, 4 H), 4.12 (s, 2 H), 2.60 (s, 3 H), 2.28 (s, 3 H).
EXAMPLE 38 Preparation of N,N′-(1,3-Phenylene)diacetamidine
Prepared from 1,3-phenylene-diamine using 2 equivalents of intermediate C. Recrystallization from MeOH/Et2O provided 1.55 g (53%) of title compound as a white solid: mp 256°-258° C.; 1H NMR (D2O, 300 MHz) δ 7.56 (t, 1 H. J=8.1 Hz), 7.36-7.20 (m, 3 H), 2.28 (s, 6 H).
EXAMPLE 39 Preparation of N-(3-Hydroxyphenyl)acetamidine
Prepared from 3-aminophenol using intermediate C. Trituration with MeOH/Et2O provided 1.9 g (90%) of title compound as a white solid: mp 115°-118° C.; 1H NMR (D2O, 300 MHz) δ 7.26 (t, 1 H, J=8.1 Hz), 6.81 (d, 1 H, 8.1 Hz), 6.73 (d, 1 H, J=8.1 Hz), 6.66 (br s, 1 H), 2.23 (s, 3 H).
EXAMPLE 40 Preparation of N-(3-(Hydrazinomethyl)phenyl) acetamidine
A solution of 1.0 g (5.3 mmol) of 3-nitrophenylhydrazineoHCl in 66 ml of THF was treated with 33 ml of saturated NaHCO3 followed by 1.15 g (5.3 mmol, 1 equiv) of BOC2O. After stirring overnight, the reaction was diluted with H2O and extracted with Et2O. The combined organic layers were washed with brine, dried (MgSO4), filtered, and concentrated in vacuo to give 1.33 g (100%) of a yellow solid that was used immediately in the next reaction. A solution of 1.33 g (5.3 mmol) of the crude intermediate in 50 ml of EtOAc at 25° C. was treated with 200 mg of 10% palladium on carbon and placed on a Parr hydrogenator under H2 until gas consumption ceased. The reaction was filtered through a pad of celite washing with EtOAc, and the filtrate was concentrated in vacuo to give 1.18 g (100%) of a yellow solid that was used immediately in the next reaction. The title compound was prepared as in example 21 using the above intermediate aniline and intermediate C. After removal of EtOH, 10 ml of 1,4-dioxane was added followed by 1 ml of 5.9M HBr in AcOH. After stirring for 30 min Et2O was added, and a solid was collected by filtration. The solid was recrystallized from MeOH/EtOAc to give 0.78 g (45%) of title compound as a brown solid: mp 218°-220° C.; 1H NMR (D2O, 300 MHz) δ 7.38 (t, 1 H, J=8.1 Hz), 6.96-6.88 (m, 2 H), 6.81 (t, 1 H, J=2.1 Hz), 2.26 (s, 3 H).
EXAMPLE 41 Preparation of N-(4-(Aminomethyl)phenyl) acetamidine
A solution of 1. 15 g (6.1 mmol) of 4-nitrobenzylamineoHCl in 76 ml of THF was treated with 38 mL of saturated NaHCO3 followed by 1.33 g (6.1 mmol, 1 equiv) of BOC2O. After stirring overnight the reaction was diluted with H2O and extracted with Et2O. The combined organic layers were dried (MgSO4), filtered, and concentrated in vacuo to give 1.54 g (100%) of 4-(N-tert-butoxycarbonyl)-nitrobenzylamine that was used immediately in the next reaction.
A solution of 1.54 g (6.1 mmol) of the above compound in 50 ml of EtOAc was treated with 150 mg of 10% palladium on carbon and placed on a Parr hydrogenator under H2 under gas consumption ceased. The reaction was filtered through a pad of celite washing with EtOAc, and the filtrate was concentrated in vacuo to give 1.36 g (100%) of intermediate aniline. The title compound was prepared from 1.36 g (6.1 mmol) of the above aniline as in example 21 using intermediate C. After EtOH removal, 10 ml of 1,4-dioxane was added followed by 1.2 ml of 5.9M HBr in AcOH. After stirring for 5 min Et2O was added, and a solid was collected by filtration. The solid was recrystallized from MeOH/EtOAc to give 1.2 g (61%) of title compound as a white solid: mp 256°-258° C.; 1H NMR (D2O, 300 MHz) δ 7.47 and 7.28 (AB quartet, 2 H, J=8.4 Hz), 4.10 (s, 2 H), 2.28 (s, 3 H).
EXAMPLE 42 Preparation of N-(1,2,3,4-Tetrahydroisoquinolin-7-yl)acetamidine
A solution of 10.5 g (78.8 mmol) of 1,2,3,4-tetra-hydroisoquinoline in 55 ml of concentrated H2SO4 at 0° C. was treated with 10 g (98.9 mmol, 1.25 equiv) and warmed to 25° C. After stirring for 48 h, ice was added followed by NH4OH. The aqueous layer was extracted with CH2Cl2, and the combined organics were dried (MgSO4), filtered, and concentrated to a volume of 100 ml. The solution was treated with 80 ml of 1M HCl in Et2O followed by Et2O. A solid was collected and recrystallized from H2O/acetone to give 6.0 g (36%) of 7-nitro-1,2,3,4-tetrahydroisoquinolineoHCl. A solution of 1.0 g (4.7 mmol) of 7-nitro-1,2,3,4-tetrahydroisoquinolineoHCl in 58 ml of THF was treated with 29 ml of saturated NaHCO3 followed by 1.02 g (4.7 mmol, 1 equiv) of BOC2O. After stirring overnight the reaction was diluted with H2O and extracted with Et2O. The combined organic layers were dried (MgSO4), filtered, and concentrated in vacuo. Pufication by flash silica gel column chromatography eluting with hexanes/Et2O (2:1) provided 1.08 g (83%) of N-tert-butoxycarbonyl-7-nitro-1,2,3,4-tetra hydroisoquinoline. A solution of 1.08 g (3.88 mmol) of the above nitroaromatic in 50 ml of EtOAc was treated with 100 mg of 10% palladium on carbon and placed on a Parr hydrogenator under H2 until gas consumption ceased. The reaction was filtered through a pad of silica gel washing with EtOAc, and the filtrate was concentrated in vacuo to give 964 mg of an intermediate aniline that was used immediately in the next reaction. The title compound was prepared as in example 21 using 0.964 g (3.88 mmol) of the above aniline and intermediate C. After EtOH removal, 10 ml of 1,4-dioxane was added followed by 0.75 ml of 5.9M HBr in AcOH. After stirring 5 min Et2O was added, and a solid was collected. Recrystallization from MeoH/EtOAc provided 530 mg (39%) of title compound as a white solid: mp undefined; 1H NMR (D2O, 300 MHz) δ 7.29 (d, 1 H, J=8.4 Hz), 7.12 (d, 1 H, J=8.4 Hz), 7.06 (br s, 1 H), 4.27 (s, 2 H), 3.41 (t, 2 H, J=6.6 Hz), 3.02 (t, 2 H, J=6.6 Hz), 2.26 (s, 3 H).
EXAMPLE 43 Preparation of N-(1H-Indazol-6-yl)acetamidine
The title compound was prepared from 6-aminoindazole as in example 21 using intermediate C. Recrystallization from MeOH/EtOAc provided 900 mg (70%) of title compound as a brown solid: mp 244°-246° C.; 1H NMR (DMSO, 300 MHz) δ 13.30 (s, 1 H), 11.23 (s, 1 H), 9.41 (s, 1 H), 8.53 (s, 1 H), 8.14 (s, 1 H), 7.90 (d, 1 H, J=8.4 Hz), 7.50 (s, 1 H), 6.98 (d, 1 H, J=8.4 Hz), 2.34 (s, 3 H).
EXAMPLE 44 Preparation of N,N′-(3,3′-(Iminodimethylene) diphenyl)diacetamidine
A solution of 1.0 g (4.63 mmol) of 3-nitrobenzyl bromide in 20 ml of DMPU was treated with 873 mg (4.63 mmol, 1 equiv) of 3-nitrobenzylamineoHCl followed by 1.5 g (13.9 mmol, 3 equiv) of Na2CO3. After stirring at 100° C. for 1 h, the reaction was cooled to 25° C. and treated with 1.06 g (4.63 mmol, 1 equiv) of BOC2O. After stirring for 48 h, the reaction was poured into H2O and extracted with hexanes/EtOAc (1:1). The combined organic layers were dried (MgSO4), filtered, and concentrated in vacuo. Purifcation by flash silica gel column chromatrography eluting with hexanes/Et2O (1:1) provided 1.26 g (70%) of bis-nitroaromatic intermediate. A solution of 1.26 g (3.25 mmol) of the above compound in 50 ml of EtOAc was treated with 150 mg of 10% palladium on carbon and placed on a Parr hydrogenator under H2 until gas consumption ceased. The reaction was filtered through a pad of celite washing with EtOAc, and the filtrate was concentrated in vacuo to give 1.07 g (100%) of an oil that was used directly in the next reaction. The title compound was prepared from 1.06 g (3.25 mmol) of the above diamine as in Example 21 using 2 equivalents of intermediate C. After EtOH removal, 10 ml of 1,4-dioxane was added followed by 0.75 ml of 5.9M HBr in AcOH. After stirring for 5 min Et2O was added and stirring was continued for 2 h. A solid was collected and recrystallized from MeOH to give 708 mg (40%) of title compound as a white solid: mp 282°-283° C.; 1H NMR (D2O, 300 MHz) δ 7.54-7.25 (m, 8 H), 4.23 (s, 4 H), 2.28 (s, 6 H).The following compound (45) was prepared in an analogous fashion:
EXAMPLE 45 Preparation of N-(3-((Hydroxyamino)methyl) phenyl)acetamidine
The title compound was prepared from 482 mg (6.94 mmol) of hydroxylamine and intermediate C for the amidine formation. Recrystallization from MeOH/EtOAc provided 600 mg (47%) of tide compound as a white solid: mp 214°-215° C.; 1H NMR (D2O, 300 MHz) δ 7.5-7.25 (m, 2 H), 7.36-7.28 (m, 2 H), 4.35 (s, 2 H), 2.28 (s, 3 H).
EXAMPLE 46 Preparation of N-(3-(1H-Pyrazol-3-yl)phenyl) acetamidine
A solution of 5.0 g (30.3 mmol) of 3-nitroacetophenone in 16 ml of DMF was treated with 4.8 mL of (MeO)2CHNMe2 and heated to 120° C. for 24 h. After cooling to 25° C., the reaction poured into 1N HCl and extracted with hexanes/EtOAc (1:1). The combined organic layers were washed with brine, dried (MgSO4), filtered, and concentrated in vacuo to give 1.88 g (28%) of intermediate.
A solution of 940 mg (4.27 mmol) of the above compound in 34 ml of MeOH and 8.5 ml of H2O was treated with 0.855 ml (17.6 mmol) of H2NNH2oH2O and heated at reflux for 2 h. After cooling to 25° C., the reaction was poured into 1N HCl and extracted with EtOAc. The combined organic layers were dried (MgSO4), filtered, and concentrated in vacuo to give 808 mg (100%) of 1-(1H-pyrazol-3-yl)-3-nitrobenzene.
A solution of 808 mg (4.27 mmol) of the above intermediate in 21 ml of CH2Cl2 was treated with a catalytic amount of DMAP followed by 918 mg (4.27 mmol, 1 equiv) of BOC2O. After stirring overnight, the reaction was concentrated in vacuo and used immediately in the next reaction.
A solution of 1.23 g (4.27 mmol) of the above intermediate in 50 ml of EtOAc was treated with 150 mg of 10% palladium on carbon and placed on a Parr hydrogenator under H2 atmosphere until gas consumption ceased. The reaction was filtered through a pad of celite washing with EtOAc, and the filtrate was concentrated in vacuo to give an oil that was used immediately in the next reaction.
The title compound was prepared from 1.1 g (4.27 mmol) of the above intermediate as in Example 21 using intermediate C. After EtOH removal, 10 ml of 1,4-dioxane was added followed by 0.80 ml of 5.9M HBr in AcOH. After stirring for 30 min Et2O was added, and stirring was continued for 2 h. A solid was collected and recrystallized from EtOH/EtOAc/Et2O to give 381 mg (25%) of title compound as a brown solid: mp 224°-226° C.; 1H NMR (D2O, 300 MHz) δ 7.81 (d, 1 H, J=2.4 Hz), 7.67 (dd, 1 H, J=8.1, 1.2 Hz), 7.55 (br s, 1 H), 7.49 (t, 1 H, J=8.1 Hz), 7.25 (br d, 1 H, J=8.1 Hz), 6.75 (d, 1 H, J=2.4 Hz), 2.28 (s, 3 H).
EXAMPLE 47 Preparation of N-(3-(Morpholinomethyl)phenyl) acetamidine2HBr
A solution of 1.0 g (4.63 mmol) of 3-nitrobenzyl bromide in 30 ml of toluene was treated with 0.806 ml (9.26 mmol, 2 equiv) of morpholine and heated to reflux for 3 h. After cooling to 25° C. EtOAc was added, and the organic layer was washed with 1N NaOH, dried (MgSO4), filtered, and concentrated in vacuo to give 1.03 g (100%) of an oil.
The crude oil from above was dissolved in 50 ml of EtOAc, treated with 100 mg of palladium on carbon, and placed on a Parr hydrogenator under H2 for 1.5 h. The mixture was filtered through a pad of silica gel washing with EtOAc/MeOH (10:1), and the filtrate was concentrated in vacuo to give 900 mg of an oil.
The title compound was prepared as in Example 21 from 890 mg (4.63 mmol) of the above oil using intermediate C. After EtOH removal, 10 ml of 1,4-dioxane was added followed by 0.90 ml of 5.9M HBr in AcOH. After stirring for 5 min Et2O was added, and a solid was collected. Recrystallization from EtOH/EtOAc provided 938 mg (51%) of title compound as a white solid: mp 219°-220° C.; 1H NMR (D2O, 300 MHz) δ 7.56-7.28 (m, 4 H), 4.28 (s, 2 H), 3.93 (br s, 2H), 3.63 (br s, 2 H), 3.40-3.00 (m, 4 H), 2.28 (s, 3 H).
The following compounds (48-50) were made in an analogous fashion:
EXAMPLE 48 Preparation of N-(3-(1H Pyrazol-1-ylmethyl) phenyl)acetamidineo2 HBr
The title compound was prepared from pyrazole as in Example 47 utilizing intermediate C for the amidine formation. Recrystallization from MeOH/EtOAc provided 960 mg (55%) of a white solid: 218°-220° C.; 1H NMR (D2O, 300 MHz) δ 7.79 (s, 1 H), 7.63 (s, 1 H), 7.40 (t, 1 H, J=7.8 Hz), 7.24-7.13 (m, 2 H), 7.03 (s, 1 H), 6.38 (m, 1 H), 5.35 (s, 2 H), 2.23 (s, 3 H).
EXAMPLE 49 Preparation of N-(3-((Dimethylamino)methyl) phenyl) acetamidineo2HBr
The title compound was prepared from 2M HNMe2 in THF as in Example 47 utilizing intermediate C for the amidine formation. Recrystallization from MeOH/EtOAc provided 960 mg (56%) of a white solid: mp 242°-243° C.; 1H NMR (D2O, 300 MHz) δ 7.58-7.28 (m, 4 H), 4.23 (s, 2 H), 2.73 (s, 6 H), 2.28 (s, 3 H); low resolution MS (CI) 192 (MH+); Anal. Calcd. for C11H17N3o2HBr: C, 37.42; H, 5.42; N, 11.90; Br, 45.26. Found: C, 37.45; H, 5.46; N, 11.81; Br, 45.16.
EXAMPLE 50 Preparation of N-(3-((2-pyridyiamino)methyl) phenyl)acetamidineo2HBr
A solution of 1.0 g (4.63 mmol) of 3-nitrobenzyl bromide in 30 ml of toluene was treated with 872 mg (9.26 mmol, 2 equiv) of 2-aminopyridine and heated to reflux for 4 h. Upon cooling to 25° C. the reaction mixture was basified with 1N NaOH and extracted with EtOAc. The combined organic layers were dried (MgSO4), filtered, and concentrated in vacuo to an oil that was used in the next reaction.
A solution of 1.06 g (4.63 mmol) of the above amine in 30 ml of THF was treated with 1.5 g (6.95 mmol, 1.5 equiv) of BOC2O and stirred 16 h. The reaction was treated with 1.5 g (6.95 mmol, 1.5 equiv) of BOC2O and stirred an additional 7.5 h. The reaction was diluted with saturated NaHCO3 and extracted with Et2O. The combined organic layers were dried (MgSO4), filtered, and concentrated in vacuo. Purification by flash silica gel column chromatrography eluting with hexanes/EtOAc (3:1) provided 411 mg (27%) of an oil that was used in the next reaction.
A solution of 411 mg (1.25 mmol) of the above nitroaromatic in 20 ml of EtOAc was treated with 100 mg of 10% palladium on carbon and placed on a Parr hydrogenator under H2 for 3 h. The reaction was filtered through celite washing with EtOAc, and the filtrate was concentrated in vacuo to give 374 mg (100%) of an oil.
The title compound was prepared from 374 mg (1.25 mmol) of the above oil as in example 47 using intermediate C. After removal of EtOH, 5 ml of 1,4-dioxane was added following by 0.30 ml of 5.9M HBr in AcOH. After stirring for 5 min Et2O was added, and stirring was continued overnight. A solid was collected and recrystallized from MeOH/EtOAC to give 270 mg (54%) of title compound as a white solid: mp 247°-248° C.; 1H NMR (D2O, 300 MHz) δ 7.76 (ddd, 1 H, J=9.2, 7.2, 1.8 Hz), 7.65 (d, 1 H, J=6.3 Hz), 7.41 (t, 1 H, J=7.6 Hz), 7.33 (d, 1 H, J=7.6 Hz), 7.22-7.13 (m, 2 H), 6.88 (d, 1 H, J=9.2 Hz), 6.77 (t, 1 H, J=6.3 Hz), 4.53 (s, 2 H), 2.25 (s, 3 H).
EXAMPLE 51 Preparation of S-(3-(Acetimidoylamino)benzyl) isothioureao2HBr
A solution of 1.0 g (4.63 mmol) of 3-nitrobenzyl bromide in 10 ml of acetone was treated with 352 mg (4.63 mmol, 1 equiv) of thiourea and stared for 3 h. The reaction was filtered to give 1.29 g (96%) of a white solid that was used directly in the next reaction.
A solution of 1.29 g (4.41 mmol) of the above compound in 50 ml of EtOH was treated with 200 mg of 10% palladium on carbon and placed on a Parr hydrogenator under H2 atmosphere overnight. The reaction mixture was filtered through a pad of celite washing with EtOH, and the filtrate was concentrated in vacuo to give 1.26 g (100%) of an orange solid that was used immediately in the next reaction.
The title compound was prepared from 1.16 g (4.41 mmol) of the above intermediate as in Example 21 using intermediate C. Recrystallization from MeOH/EtOAc provided 672 mg (40%) of title compound as a brown solid: mp 228°-230° C.; 1H NMR (D2O, 300 MHz) δ 7.46-7.12 (m, 4 H), 4.31 (s, 2 H), 2.27 (s, 3 H).
EXAMPLE 52 Preparation of N-(3(Aminomethyl)phenyl)-2-fluoroacetamidine
Preparation of intermediate Tert-butyl N-(3-nitro) benzyl-carbamate
To a 0° C. solution of 30 g (0.159 mol) of 3-nitrobenzylamine hyydrochloride in MeOH (100 ml), THF (100 ml) and 48.8 ml triethylamine was added a solution of 38.2 g (0.175 mol) di-tert-butyl dicarbonate in THF (200 ml) over 60 min. After 1 hr, the solution was concentrated, diluted with 100 ml water, and extracted with EtOAc (2×100 ml). The dried (Na2SO4) solution was concentrated and purified by silica gel chromatography eluting with 10%-30% EtOAc in hexanes to yield 38 g (95%) of tert-butyl N-(3-nitro)benzylcarbamate.
Amidine synthesis:
A solution of 10 g (39.64 mmol) of tert-butyl N-(3-nitro) benzyl -carbamate in 100 ml EtOAc was hydrogenated. under 55 psi H2 in the presence of 1 g of 10% Pd on carbon for 90 min. The residue after filtration and concentration was taken into 100 ml of absolute ethanol at 0° C. and 16 g (50.8 mmol) of intermediate E was added. The solution was stirred for 16 h and concentrated to a volume of 15 ml before 500 ml of ether was added with rapid stirring. The resulting residue was taken into 75 ml of acetic acid and 15 ml of 30% HBr in acetic acid solution was added. After 15 min 500 ml of ether was added, the mixture stirred for 30 min, and the pale yellow solids collected via filtration to yield 13.5 g (99%). Recrystallization of 7 g from 30 ml MeOH and 150 mL EtOAC gave 6.0 g of white solid N-(3-(Aminomethyl) phenyl)-2-fluoroacetamidine. Mass Spectrum (CI)182 (MH+, 9.7%). 1H NMR (300 MHz, DMSO) δ 7.61-7.32 (m, 4H), 5.5 (d, J=45.1 Hz, 2H), 4.08 (s, 2H).
EXAMPLE 53 Preparation of N-(3-(2-Aminoethyl)phenyl) acetamidine
3-Nitrophenethyl alcohol (2.5 g) was hydrogenated (55 psi, 20° C.) in MeOH (100 ml) in the presence of di-tert-butyl dicarbonate (3.6 g) and 750 mg of 10% palladium on carbon to give 3.7 g (100%) of BOC-protected intermediate (mass spec. 238.0, MH+). 3.55 g of this alcohol intermediate was converted to azide via the bromide(CBr4, PPh3, CH2Cl2, then NaN3 in DMF) to provide 1.65 g. Reduction of the azide (1.16 g, EtOAc, Pd/C, 20° C., 55 psi H2) followed by protection (K2CO3, CH2Cl2, H2O, CBz-Cl) gave 1.6 g (100%) of intermediate. The BOC protecting group was removed at 0° C. in CH2Cl2 with TFA. The crude material was free based with NaHCO3 and the resulting residue (with intermediate A) was converted to the intermediate N-(3-(2-(Benzyloxycarbonyl) aminoethyl)phenyl) acetamidine (1.5 g) analogous to example 1. A MeOH (75 ml) and 3.0M HCl in EtOH (25 ml) solution of this acetamidine (1.2 g) was hydrogenated at 55 psi H2 at 20° C. for 4 h. Filtration through celite and concentration gave the title compound. Mass Spectrum (CI)178.2 (MH+, 100%). 1H NMR (300 MHz, D2O) δ 7.4-7.1 (m, 4H), 3.14 (t, J=7.1 Hz, 2H), 2.89 (t, J=7.1 Hz, 2H), 2.25 (s, 3H).
EXAMPLE 54 Preparation of N-(3-(Aminomethyl)benzyl) propionamidine
Prepared from tert-butyl N-(3-(aminomethyl)benzyl carbamate (1.0 g) and intermediate J as in example 2 to yield 1.25 g of white solid. A 1.0 g portion of this solid was recrystallized from MeOH/EtOAc to yield 0.93 g of the title compound. 1H NMR (200 MHz, D2O) δ 7.5-7.38 (m, 4H), 4.52 (s, 2H), 4.18 (s, 2H), 2.53 (q, J=7.7 Hz, 2H), 1.25 (t, J=7.7 Hz, 3H).
EXAMPLE 55 Preparation of 2-Amino-N-(3-Aminomethyl)phenyl) acetamidine
Prepared from tert-butyl N-(3-(aminomethyl)benzyl) carbamate and intermediate I analogous to example 2. 1H NMR (200 MHz, D2O) δ 4.25 (4H, d, J=5.5 Hz), 7.78-7.40 (4H, m). Mass Spectrum (CI) 179.1 (MH+, 100%).
EXAMPLE 56 Preparation of N-(3-Aminomethyl)phenyl)-2-(methylthio)acetamidine
Prepared from tert-butyl N-(3-(aminomethyl)benzyl) carbamate and intermediate H analogous to example 1. 1H NMR (200 MHz, DMSO) δ 2.30 (3H, s), 3.64 (2H, s), 4.12 (2H, s), 7.65-7.32 (4H, m). Mass Spectrum (CI) 210.0 (MH+, 60.5%).
EXAMPLE 57 Preparation of N-(1,2,3,4-tetrahydro-7-isoquinolyl) methyl)acetamidineo2HBr
To a solution of 5.0 g (37.5 mmol) of 1,2,3,4,-tetra-hydroisoquinoline in 23 ml of concentrated H2SO4 at 25° C. was treated with 6.7 g (37.5 mmol, 1 equiv) of N-hydroxymethylphthalimide and stirred for 7 days. The reaction was poured into H2O, basified with solid NaHCO3, and extracted with Et2O. The combined organics were dried (MgSO4), filtered, and concentrated in vacuo. The residue was dissolved in Et2O and acidified with 1M HCl in Et2O. The solid was collected and recrystallized from MeOH/Et2O to give 1.7 g (10%) of intermediate that was used in the next reaction.
A solution of 500 mg (1.52 mmol) of the above compound in 19 ml of THF was treated with 9 ml of saturated NaHCO3 followed by 332 mg (1.52 mmol, 1 equiv) of BOC2O. After stirring for 48 h, the reaction was diluted with H2O and extracted with Et2O. The combined organic layers were dried (MgSO4), filtered, and concentrated in vacuo. Purification by flash silica gel column chromatography eluting with hexanes/Et2O (1:1) provided 474 mg (79%) of N-protected tetrahydroisoquinoline.
A solution of 474 mg (1.21 mmol) of the above compound in 12 ml of EtOH was treated with 0.117 ml (2.41 mmol, 2 equiv) of H2NNH2oH2O and stirred for 36 h. The reaction was diluted with CH2Cl2 and filtered. After concentration in vacuo, the residue was dissolved in CH2Cl2 and filtered. The filtrate was concentrated in vacuo and used in the next reaction.
The title compound was prepared from the above intermediate as in example 21 using intermediate C. After EtOH removal, 2 ml of 1,4-dioxane was added followed by 0.50 ml of 5.9M HBr in AcOH. After stirring for 15 min Et2O was added, and the supernatant was decanted. The residue was triturated with isopropanol overnight. Filtration provided 272 mg (62%) of title compound as an off-white solid: mp 215°-218° C.; 1H NMR (D2O, 300 MHz) δ 7.12-6.88 (m, 3 H), 4.21 (s, 2 H), 4.12 (s, 2 H), 3.27 (t, 1 H, J=6.3 Hz), 2.87 (t, 1 H, J=6.3 Hz), 2.01 (s, 3 H).
EXAMPLE 58 Preparation of 2-Fluoro-N-(3-(2-hydroxymethyl) phenyl)acetamidine
The title compound (2.19 g) was prepared as a pale yellow solid from 3-aminophenethyl alcohol (1.0 g) and intermediate D (2.32 g) as in example 1. 1H NMR (300 MHz, D2O) δ 7.5 (t, J=7.5 Hz, 1H), 7.37 (d, J=7.8 Hz, 1H), 7.2 (m, 2H), 5.4 (d, J=44.9 Hz, 2H), 3.83 (t, J=6.4 Hz), 2.87 (t, J=6.4 Hz, 2H). Mass Spectrum (CI) 197.0 (MH+, 100%)
EXAMPLE 59 Preparation of N-(3-Amino-5-indanyl)acetamidine
6-Nitroindan-1-one (18.1 g, 102 mmol) was dissolved in ethanol (400 ml) and reduced using Pd (5%) on carbon (2.0 g) and 35 psi hydrogen pressure on a Parr apparatus. Filtration on celite followed by evaporation gave 6-aminoindan-1-one (13.7 g, 93 mmol). NMR (DMSO) 7.2 (d, J=7.7Hz, 1H), 6.9 (dd, Jab=7.7Hz, J ax=2.3 Hz, 1H), 6.75 (d, J=2.3Hz, 1H), 5.3 (br s, 2H), 2.9 (t, J=5.6 Hz, 2H), 2.55 (t, J=5.6 Hz, 2H).
6-Aminoindan-1-one (10.0 g, 68 mmol) was treated with pyridine (50 ml) and hydroxylamine-O-benzyl ether.HCl (11.4 g, 71.3 mmol) and heated to 50° C. under N2 for 40 min. The mixture was evaporated in vacuo and diluted with CH2Cl2 (300 ml). Filtration gave a solid which was washed with a small volume of CH2Cl2 and dried in vacuo to give 6-Amino-1-O-benzyloximinoindane (14.0 g, 48.5 mmol) as the HCl salt. NMR (DMSO) 10.5-9.0 (br s, 3H), 7.5-7.3 (m, 8H), 5.2 (s, 2 H), 3.05 (m, 2H), 2.9 (m, 2H).
6-Amino-1-O-benzyloximinoindane.HCl (5.0 g, 17.3 mmol) was treated with 1.0M BH3-THF (86 ml) and warmed under N2 to 40° C. for 23 hrs. The mixture was evaporated and diluted with CH2Cl2 and quenched by dropwise adition of MeOH. The solvent was evaporated and 1.0N HCl (50 ml) was added and the mixture warmed to 50° C. for 1hr. After cooling, 1.0N NaOH (50 ml) was added and the pH adjusted to 9.5 with additional 1.0N NaOH. The mixture was extracted with CH2Cl2 and the extract evaporated onto silica gel and chromatographed using CH2Cl2 with 30 volume % MeOH. Evaporation of appropriate fractions gave 1,6-diaminoindane (2.0 g, 78%). NMR (DMSO-d6) 6.8 (d, J=6.8 Hz, 1H), 6.57 (s, 1H), 6.4 (d, J=6.8 Hz, 1H), 4.8 (brs, 2H) 4.0 (t, J=7Hz, 1H), 2.75-2.6 (m, 2H), 2.3-2.2 (m, 1H), 1.8 (br s, 2H, NH2), 1.6-1.4 (m, 1H).
1,6-Diaminoindane ( 0.5 g, 3.4 mmol) was stirred in CH2Cl2 (10 ml) and cooled to 0° C. Di-tert-butyl dicarbonate (0.74 g, 3.4 mmol) in CH2Cl2 (3 ml) was added dropwise over 10 min and the solution stirred overnight. The solution was evaporated in vacuo and diluted with EtOH (20 ml) and cooled to 0° C. Intermediate C was added and the mixture allowed to warm to 20° C. and stirred for 90 min. Dropwise addition of 30% HBr/HOAc (1.5 ml) with stirring gave after 70 min a white solid which was collected and washed with a small volume of CH2Cl2 and dried in vacuo yielding N-(3-Amino-5-indanyl)acetamidine (1.1 g, 93%) as the 2HBr salt. NMR (DMSO-d6) 8.5 (brs, NH), 8.4 (brs, NH), 7.55 (s, 1H), 7.5 (s, 1H), 7.3 (d, J=7.0 Hz, 1H), 4.8 (m, 1H), 3.8 (brs, NH), 3.2-3.0 (m, 1H), 3.0-2.8 (m, 1H), 2.6-2.5 (m, 1H), 2.4 (s, 3H, CH3), 2.1-2.0 (m, 1H).
EXAMPLE 60 Preparation of N-(1-Amino-4-indanyl)acetamidine
4-Nitroindan-1-one was converted to the 1-oximinobenzylether and reduced to 1-amino-4-nitroindane using BH3-THF by the methods described in example 59.
1-Amino-4-nitroindane (0.4 g, 2.24 mmol) was dissolved in CH2Cl2 (10 ml) and treated with t-BOC anhydride (0.59 g, 2.7 mmol). After 18 hrs the solvent was removed in vacuo and the residue dissolved in EtOH (50 ml) and reduced using 5% Pd/C (0.2 g) and H2 at 32 psi on a Parr apparatus. Evaporation of the solvent to a final volume of 20 ml followed Filtration on celite. The intermediate was treated with intermediate C (0.68 g, 2.3 mmol) and stirred for 2 hrs. The solvent was removed in vacuo and the residue dissolved in dioxane (15 ml) and treated with 30% HBr-HOAc. After 90 min the crystaline solid that resulted was collected and washed with a small volume of CH2Cl2 and dried in vacuo to give N-(1-Amino-4-indanyl)acetamidine (0.60 g, 99%) as the HBr salt. NMR (D2O) 7.6 (d, J=7 Hz, 1H), 7.5 (dd, J=7 Hz, 1H), 7.3 (d, J=7 Hz, 1H), 4.9 (m, 1H), 3.1-2.8 (m, 2H), 2.6 (m, 1H), 2.4 (s, 3H, CH3), 2.1 (m, 1H).
EXAMPLE 61 Preparation of N-6-(Aminomethyl)-1-indanyl) acetamidine
6-Cyanoindan-1-one (prepared using the procedure of Allinger and Jones, JOC 1962, p70. vol 27 for the tetralone analogue) (3.86 g, 24.5 mmol) was converted to the 1-oxime-O-benzyl ether and reduced with BH3-THF by the methods described in example 59 to give 1-amino-6-(aminomethyl)indane. The diamine was isolated in 31% yield as the 2 HCl salt by treatment of an ether solution with 4.0N HCl in dioxane. 1-Amino-6-aminomethylindane 2HCl (0.5 g, 2.1 mmol) was stirred in EtOH (20 ml), cooled to 0° C. and treated with NEt3 (0.59 ml, 4.2 mmol). Intermediate A (0.43 g, 2.1 mmol) was added and the mixture was allowed to warm to 20° C. and stir overnight. The white crystaline product was collected and washed with a small volume of ether and dried in vacuo to give N-(6-(Aminomethyl)-1-indanyl)acetamidine (0.27 g, 35%) as the 2 HCl salt NMR (D2O) 7.45-7.25 (m, 3H), 4.8 (m, 1H), 4.45 (s, 2H), 3.2-2.85 (m, 2H), 2.6)m, 1H), 2.2 (s, 3H, CH3), 2.1 (m, 1H).
EXAMPLE 62 Preparation of N-((3-Amino-5-indanyl)methyl) acetamidine
1-Amino-6-aminomethylindane . 2 HCl (2.0 g, 8.5 mmol) was stirred in MeOH and cooled to 0° C. and treated with Et3N (1.8 ml, 12.9 mmol). Di-tert-Butyl dicarbonate (1.0 g, 4.6 mmol) in CH2Cl2 (3 ml) was added dropwise over 10 min and the mixture allowed to warm to 20° C. and stirred for 60 min. The mixture was evaporated in vacuo followed by treatment with CH2Cl2 (15 ml) gave a white solid which was collected and dried in vacuo to yield 1-amino-6-tert-butylcarbamoylmethylindane HCl (0.46 g, 18%). NMR (DMSO) 8.3 (br s, NH3), 7.4 (br s, 2H, NHCO), 7.25 (d, J=7.6 Hz, 1H), 7.2 (d, J=7.6 Hz), 4.7 (t, J=6 Hz, 1H), 4.13 (d, J=6 Hz, 2H), 3.15-2.95 (m, 1H), 2.95-2.75 (m, 1H), 2.5-2.4 (m, 1H), 2.1-1.9 (m, 1H), 1.4 (s, 9H).
1-Amino-6-tert-butylcarbamoylmethylindane hydrochloride (0.15 g, 0.57 mmol) was stirred in EtOH (3 ml) at 0° C. and treated with Et3N (0.08 ml, 0.57 mmol). Intermediate A (0.115 g, 0.57 mmol) was added and the mixture allowed to warm to 20° C. and stir overnight. The mixture was evaporated in vacuo and the residue dissolved in dioxane (3 ml) and treated dropwise with 4.0N HCl/dioxane (1.0 ml). On standing at 5° C. overnight, a white crystaline solid formed and was collected and washed with a small volume of cold dioxane and dried in vacuo to give N-(3-Amino-5-indanyl) methyl)acetamidine (0.10 g, 63%) as the 2 HCl salt. NMR (D2O) 7.4-7.3 (m, 3H), 5.2 (m, 1H), 4.1 (s, 2H), 3.1-2.8 (m, 2H), 2.6 (m, 1H), 2.2 (s, 3H, CH3), 2.0 (m, 1H).1H), 3.0-2.8 (m, 1H), 2.6-2.5 (m, 1H), 2.4 (s, 3H, CH3), 2.1-2.0 (m, 1H).
EXAMPLE 63 Preparation of 1-Amino-4-(1-iminoethylamino)but-2-yne 2.5hydrochloride
Preparation of 1-Azido-4-(butoxycarbonylamino)but-2-yne
Hexamethylenetetramine (28.27 g) and 1,4-dichlorobut-2-yne (24.84 g) were refluxed in chloroform (165 ml) for 20 min. Upon cooling to room temperature the resulting precipitate was filtered off and sucked dry. The mother liquor was concentrated to one quarter volume and a further crop of precipitate obtained. Total yield of complex=46.10 g.
The above complex (6.7 g) was added to a mixture of ethanol (100 ml) and concentrated hydrochloric acid (9.4 ml) and the mixture refluxed for 3 h. On cooling, the precipitate was filtered and discarded. The filtrate was concentrated until it became cloudy at which point it was diluted with diethyl ether (4 volumes). The resulting precipitate was filtered, washed with more diethyl ether and sucked dry. The filtrate was concentrated to a small volume, more diethyl ether added and the resulting precipitate filtered off and sucked dry. The total yield of 1-amino-4-chlorobut-2-yne hydrochloride was 2.924 g.
1-Amino-4-chlorobut-2-yne hydrochloride (6 g) and di-t-butyldicarbonate (9.354 g) in dry THF (60 ml) were treated with diethylisopropylamine (7.52 ml) and the mixture stirred overnight at room temperature. After this time the precipitate was filtered off and the filtrate concentrated in vacuo. The residue was partitioned between diethyl ether and water and the organic layer washed successively with 0. 1N HCl, water and brine, and dried over MgSO4. Concentration in vacuo gave a green oil (9.205 g) which was used directly. The oil was dissolved in DMF (140 ml) and tetrabutylammonium iodide (7.92 g) and sodium azide (3.065 g) added. The mixture was heated under N2, in the dark at 60°-70° C. for 1 h. Upon cooling, diethyl ether and water were added and the organic layer washed successively with 0.1N HCl, water and brine, and dried over MgSO4. Concentration in vacuo gave an oil which was purified by column chromatography on silica gel (3/1 hexane/ethyl acetate). The fractions with Rf=0.42 (3/1 hexane/ethyl acetate) pooled and concentrated to yield 1-azido-4-(butoxycarbonylamino)but-2-yne as a yellow oil (3.049 g).
Preparation of 1-Amino-4-(iminoethylamino)but-2-yne 2.5hydrochloride
To 1-azido-4-(butoxycarbonylamino)but-2-yne (0.294 g) in dry THF (7 ml) was added triphenyl phosphine (0.386 g) and water (38 ml) and the mixture stirred overnight at room temperature. After this time S-benzyl-2-thioacetimidate hydrochloride (0.237 g) and ethanol (4 ml) were added and the mixture stirred overnight at room temperature. The mixture was concentrated in vacua, the residue partitioned between water and ethyl acetate. and the aqueous layer concentrated in vacuo. The residue was treated with ethanol and re-concentrated in vacuo (×2). The residue was tritured with diethyl ether and the ether decanted off (×2). The remaining solid was sucked dry on an oil pump to yield 1-butoxycarbonylamino-4-(1-iminoethylamino)but-2-yne hydrochloride as a white hygroscopic solid (0.332 g).
1-Butoxycarbonylamino-4-(1-iminoethylamino)but-2-yne (0.332 g) was deprotected by treatment with 4 N HCl/dioxane (3 ml) at 0° C. and stirring at 0° C. for 1h then at room temperature for 1h. After this time the mother liquor was decanted off and the sticky residue subjected to an oil pump vacuum to remove residual solvent. The resulting material was triturated with dry diethyl ether (×2), filtered off and washed with more dry diethyl ether. The yellow solid was finally dried in a drying pistol to yield 1-amino-4-(1-iminoethylamino)but-2-yne 2.5hydrochloride (0.184 g), Mpt 182°-185° C.(dec), FAB M.S. M+1+126.
EXAMPLE 64 Preparation of 1-Amino-4-(1-imino-2-fluoroethylamino)but-2-yne dihydrobromide
1-Amino-4-(1-imino-2-fluoroethylamino)but-2-ynedihydrobromide was made from 1-azido-4-(butoxycarbonylamino)but-2-yne and S-benzyl-2-fluorothioacetimidate hydrobromide to yield 1-butoxycarbonylamino-4-(1-imino-2-fluoro-ethylamino) but-2-yne hydrobromide as an intermediate.
1-Butoxycarbonylamino-4-(1-imino-2-fluoroethylamino) but-2-yne hydrobromide (500 mg) was deprotected by dissolving in glacial acetic acid (10 ml), cooling until the solution almost solidified and adding HBr in acetic acid (45% wv, 1.8 ml). The mixture was stirred with cooling for 1 h then at room temperature for 1 h. After this time the mother liquor was decanted off and the sticky residue subjected to an oil pump vacuum to remove residual solvent. The resulting material was triturated with dry diethyl ether (×2), filtered off and washed with more dry diethyl ether. The yellow solid was recrystallised from ethanol/diethyl ether and finally dried in a drying pistol to yield 1-amino-4-(1-imino-2-fluoroethylamino)but-2-yne dihydrobromide, Mpt 174°-176.5° C.(dec.), FAB M.S. M+1+144.
EXAMPLE 65 Preparationof1-(2-Aminoethoxy)-2-N-(1-iminoethyl) ethylamine2hydrochloride
Preaparation of N-(tertbutoxycarbonyl)-2-(2-aminoethoxy) ethyl azide
The title compound was prepared from 2-(2-aminoethoxy)ethanol using the procedures described for equivalent non-ether linked straight chain aminoalcohols by Mattingly (Synthesis, 1990, 366-368).
Preparation of 1-(2-Aminoethoxy)-2-N-(1-iminoethyl) ethylamine 2hydrochloride
To N-(tertbutoxycarbonyl)-2-(2-aminoethoxy)ethyl azide (0.315 g) in dry THF (10 ml) was added polymer supported triphenyl phosphine (0.46 g) and water (37 μl) and the mixture slowly stirred overnight at room temperature. After this time S-benzyl-2-thioacetimidate hydrochloride (0.352 g) and ethanol (5 ml) were added and the mixture stirred overnight at room temperature. The mixture was concentrated in vacuo, the residue partitioned between water and ether, and the aqueous layer concentrated in vacuo to furnish N-(tertbutoxycarbonyl)-1-(2-Aminoethoxy)-2-N-(1-iminoethyl) ethylamine as a white foam.
Treatment of a solution of N-(tertbutoxycarbonyl)-1-(2-Aminoethoxy)-2-N-( 1-iminoethyl) ethylamine (280 mg) in dioxan with 10 ml of 4N HCl in dioxan served to deprotect the molecule by stirring at room temperature for 1 h. At this time a 50 ml portion of ether and the suspension were vigorously stirred. The title compound was furnished as a hygroscopic solid on filtering this suspension and drying in vacuo.
FAB MS M+1+, 100%. 1H NMR (360 MHz, D2O) δ H, ppm 2.28 (1H, s, Me); 3.25 (2H, t, CH2), 3.55 (2H, t CH2), 3.82 (4H, m, 2× CH2), IR νmax (KBr disc) 3 111, 1 676, 1 643 cm−1
Biological Data
NO synthase inhibition was determined by the following procedure:
Purification of NOS from human placenta
Amion and chorion were removed from fresh placenta, which was then rinsed with 0.9% NaCl. The tissue was homogenised in a Waring blender in 3 volumes of HEDS buffer (20 mM Hepes pH 7.8, 0.1 mM EDTA, 5mM DTT, 0.2M sucrose) plus 0.1 mM PMSF. The homogenate was filtered through cheesecloth and then centrifuged at 1000 g for 20 min. The supernatant was recentrifuged at 27,500 g for 30 min. Solid ammonium sulphate was added to the supernatant to give 32% saturation. Precipitated protein was pelleted at 25,000 g and then redissolved in a minimal volume of HEDS buffer plus 0.1 mM PMSF, 10 μg/ml leupeptin and soybean trypsin inhibitor, and 1 μg/ml pepstatin. The redissolved pellet was centrifuged at 15,000 g for 10 min. To the supernatant was added {fraction (1/20)} volume at 2,5′ ADP agarose resin (Sigma), and the slurry was mixed slowly overnight. In the morning, slurry was packed into a column. The resin was sequentially washed with HEDS, 0.5M NaCl in HEDS, HEDS, and then NOS was eluted with 10 mM NADPH in HEDS. The enzyme could be concentrated by ultra filtration and quick frozen and stored at −70° C. without loss in activity for at least 3 months.
Assay for human placental NOS
NOS was assayed for the formation of citrulline following the procedure of Schmidt et al (PNAS 88 365-369, 1991) with these modifications: 20 mM Hepes, pH 7.4, 10 μg/ml calmodulin, 2.5 mM CaC12, 2.5 mM DTT, 125 μM NADPH, 10 μM tetrahydrobiopterin, 0.5 mg/ml BSA, and 1 μM L-[14C]arginine (New England Nuclear). Linearity of NOS-catalysed rate was confirmed prior to kinetic studies that used single time point determination of rate.
Purification of NOS from cytokine-induced human colorectal adenocarcinoma DLD-1 cells
DLD-1 (ATCC No. CCL 221) were grown at 37° C., 5% CO2 in RPMI 1640 medium supplemented with L-glutamine, penicillin, streptomycin, and 10% heat-inactivated fetal bovine serum. Cells were grown to confluence and then the following cocktail of cytokines were added: 100 units/ml interferon-gamma, 200 units/ml interleukin-6, 10 ng/ml tumour necrosis factor, and 0.5 ng/ml interleukin-1β At 18-24 hr post-induction, cells were harvested by scraping and washed with phosphate-buffered saline. Pelleted cells were stored at −70° C. Purification of the induced NOS was performed at 4° C. Crude extract was prepared by three cycles of freeze/thawing cells in TDGB (20 mM tris pH 7.5, 10% glycerol, 1 mM DTT, 2 μM tetrahydrobiopterin). Extract was applied directly onto a column of 2′, 5′ ADP sepharose (Pharmacia). Resin was sequentially washed with TDGB, 0.5M NaCl in TDGB, TDGB. NOS was eluted with 2 mM NADPH in TDGB. BSA was immediately added to give a final concentration of 1 mg/ml. NOS could be quick frozen and stored at −70° C. without loss in activity for at least 2 months.
Assay for inducible human NOS
The formation of citrulline were assayed as described above except that 10 μM FAD was included and calmodulin and CaCl2 excluded from the assay mix.
Purification of NOS from human brain
Human brain NOS was prepared using variations of the procedures of Schmidt et al. (PNAS 88 365-369, 1991), Mayer et al. (Fed. Eur. Biochem. Soc. 288 187-191, 1991), and Bredt and Snyder, (PNAS 87 682-685, 1990). Briefly, fresh whole brains (3 with myelinated tissue dissected away, 1050 g) were homogenised in cold buffer A (50 mM HEPES, pH 7.5 (pH at RT) and 0.5 mM EDTA, 10 mM DTT, 3.6 L total volume) with a polytron. The mixture was centrifuged at 13,000 g for 1 hour and the supernatant fluid was removed (about 2050 ml). To the supernatant fluid, solid ammonium sulphate (365 g, about 30% of saturation) was added and stirred slowly for a total of 30 minutes. The precipitate was pelleted at 13,000 g for 30 minutes and the pellet was resuspended in ˜400 ml of buffer A with 4 μM tetrahydrobiopterin, 1 μM FAD (Sigma), and 1 μM FMN (Sigma). The solution was centrifuged at 41,000 g for 60 minutes. The supernatant was removed, frozen by pouring into liquid nitrogen, and stored overnight at −70° C. The mixture was thawed and passed through at 2′, 5′ ADP-agarose column (0.4 g swelled in buffer A) at 4 ml/min. The column was washed with 100 ml buffer A, 200 ml buffer A with 500 mM NaCl, 100 ml Buffer A, then 30 ml buffer A with 5 mM NADPH. To the enzyme solution was added tetrahydrobiopterin to 10 μM, FAD and FMN to 1 μM, and Tween to 0.1%. This solution was concentrated by Centriprep-30 to a volume of approximately 500 μl. Enzyme activity was determined as described by Schmidt et al. 1991, except that 10 μM tetrahydrobiopterin was included in the assay.
The compounds of the invention exhibit NOS inhibition properties, and certain groups of the compounds exhibit selective inhibition properties against either the inducible or neuronal NOS.

Claims (16)

We claim:
1. An A method of treating a condition requiring inhibition of NO synthase, the step of administering to a mammal in need thereof an effective amount of an acetamidine derivative of formula (I):
Figure USRE037438-20011106-C00027
or a salt thereof, wherein
R1 is
hydrogen,
a C1-6 hydrocarbyl group optionally substituted by halo,
halo,
nitro,
cyano or
a group XR3 wherein X is oxygen, C(O)m wherein m is 1 or 2, S(O)n wherein n is 0, 1 or 2, or a group NR4 wherein R4 is hydrogen or C1-6 alkyl; and R3 is hydrogen, C1-6 alkyl, or a group NR5R6 wherein R5 and R6 are independently hydrogen or C1-6 alkyl; provided that R3 is not NR5R6 when X is oxygen or S(O)n;
R1a and R1b are independently selected from hydrogen and halo;
R2 is a group:
Figure USRE037438-20011106-C00028
wherein p, q and r are independently 0, 1 or 2, and R12 is selected from the group consisting of flouro, hydrogen, and NH2.
2. A method of treating a condition requiring inhibition of NO synthase, comprising the step of administering to a mammal in need thereof an effective amount of a compound of formula (1B):
Figure USRE037438-20011106-C00029
wherein R1 is
hydrogen,
a C1-6 hydrocarbyl group optionally substituted by halo,
halo,
nitro,
cyano or
a group XR3 wherein X is oxygen, C(O)m wherein m is 1 or 2, S(O)n wherein n is 0, 1 or 2, or a group NR4 wherein R4 is hydrogen or C1-6 alkyl; and R3 is hydrogen, C1-6 alkyl, or a group NR5R6 wherein R5 and R6 are independently hydrogen or C1-6 alkyl, provided that R3 is not NR5R6 when X is oxygen or S(O)n;
R1a and R1b are independently selected from hydrogen and halo, and
R14 represents one or two substituents on the phenyl ring independently selected from halo, ZR7 or a group:
Figure USRE037438-20011106-C00030
wherein Z is oxygen, C(O)m wherein m is 1 or 2, S(O)n wherein n is 0, 1 or 2, or a group NR8 wherein R8 is hydrogen or C1-6 alkyl, R7 is hydrogen, C1-6 alkyl, or a group NR9R10 wherein R9 and R10 are independently hydrogen or C1-6 alkyl, and R11 has a definition the same as for R1, or
R14 is a C1-6C1-8 hydrocarbyl group optionally substituted by one or two groups which may be the same or different, and are selected from halo, ZR7 or a group:
Figure USRE037438-20011106-C00031
3. A method of treating a condition requiring inhibition of NO synthase, comprising the step of administering to a mammal in need thereof an effective amount of a compound of formula 1C:
Figure USRE037438-20011106-C00032
wherein R1 is
hydrogen,
a C1-6 hydrocarbyl group optionally substituted by halo,
halo,
nitro,
cyano or
a group XR3 wherein X is oxygen, C(O)m wherein m is 1 or 2, S(O)n wherein n is 0, 1 or 2, or a group NR4 wherein R4 is hydrogen or C1-6 alkyl; and R3 is hydrogen, C1-6 alkyl, or a group NR5R6 wherein R5 and R6 are independently hydrogen or C1-6 alkyl, provided that R3 is not NR5R6 when X is oxygen or S(O)n;
R1a and R1b are independently selected from hydrogen and halo;
R15 is a bond or CH2; and
Y is selected from the group consisting of optionally substituted phenyl and indanyl; wherein Y is optionally substituted by one or more groups independently selected from the group consisting of halo, amino, cyano, nitro, hydroxy, and C1-6 hydrocarbyl optionally substituted by hydroxy, C1-6 alkoxy, C1-6 thioalkyl, CF3, N3N3, a group:
Figure USRE037438-20011106-C00033
wherein n is 0, 1 or 2, C(O)mB′ or S(O)nB′ wherein m is 1 or 2, n is 0, 1 or 2 and B′ is amino or C1-6 alkyl,
a group:
Figure USRE037438-20011106-C00034
wherein n is 0, 1 or 2 and D and E are independently selected from the group consisting of hydrogen, hydroxy, amino, C1-6 alkyl, —CNHCH3, —CO2 tBu,
a group:
—(CH2)n—NH—(CH2)n—A
—(CH 2)n —NH—(CH 2)n′ —A
wherein n is 0, 1 or 2, n′ is 0, 1 or 2, and A is phenyl
a group:
—(CH 2)n —G
wherein n is 0, 1 or 2 and G is —CO 2 H, or —CO 2 C 1-6 alkyl.
4. The An acetamidine derivative of claim 1 which is:
N-(3-(Hydroxymethyl)phenyl)acetamidine;
N-(3-(Aminomethyl)phenyl)acetamidine;
N-(3-((Methylamino)methyl)phenyl)acetamidine;
N-(Dimethylamino)methyl)phenyl)acetamidine;
N-(3-(Aminomethyl)phenyl)-2-fluoroacetamidine;
N-(3-(2-Aminoethyl)phenyl)acetamidine; or
a salt thereof.
5. The An acetamidine derivative of claim 1 which is:
N-(3-(Aminomethyl)benzyl)acetamidine;
N-(4-(Aminomethyl)benzyl)acetamidine;
N-(3-(Aminomethyl)benzyl)-3-fluoroacetamidine;
N-(3-(Aminomethyl)benzyl-2-aminoacetamidine;
N-(3-(Aminomethyl)benzyl)-2,2,2-trifluororacetamidine;
N-((1H-Indazol-6-yl)methyl)acetamidine; or
N-((3-Amino-5-indanyl)methyl)acetamidine; or
a salt thereof.
6. The acetamidine derivative of claim 1 5which is:
N-(3-(Aminomethyl)benzyl)acetamidine;
N-(4-(Aminomethyl)benzyl)acetamidine;
N-(3-(Aminomethyl)benzyl)-3-fluoroacetamidine;
N-(3-(Aminomethyl)benzyl)-3-aminoacetamidine;
N-((3-Amino-5-indanyl)methyl)acetamidine;
or a salt thereof.
7. A pharmaceutical formulation comprising at least one compound as defined in claim 1of formula (I):
Figure USRE037438-20011106-C00035
or a salt thereof, wherein
R 1 is
hydrogen,
a C 1-6 hydrocarbyl group substituted by halo,
halo,
nitro,
cyano or
a group XR 3 wherein X is oxygen, C(O)m wherein m is 1 or 2, S(O)n wherein n is 0, 1 or 2, or a group NR 4 wherein R 4 is hydrogen or C 1-6 alkyl; and R 3 is hydrogen, C 1-6 alkyl, or a group NR 5 R 6 wherein R 5 and R 6 are independently hydrogen or C 1-6 alkyl; provided that R 3 is not NR 5 R 6 when X is oxygen or S(O) n ;
R 1a and R 1b are independently selected from hydrogen and halo;
R 2 is a group:
Figure USRE037438-20011106-C00036
wherein p, q and r are independently 0, 1 or 2, and R 12 is selected from the group consisting of flouro, hydrogen, and NH 2 ;
together with one or more pharmaceutically acceptable carriers, diluents, or excipients.
8. A method of treating a condition requiring inhibition of NO synthase, comprising the step of administering to a mammal in need thereof an effective amount of an acetamidine derivative of claim 1.
9. The method of claim 8 1wherein the compound inhibits one of the NO synthase isoenzymes with little or no inhibition of the other isoenzymes.
10. A method for the prophylaxis or treatment of shock states resulting from overproduction of NO by iNOS, said method comprising administering an acetamidine derivative of claim 1formula (I):
Figure USRE037438-20011106-C00037
or a salt thereof, wherein
R 1 is
hydrogen,
a C 1-6 hydrocarbyl group optionally substituted by halo,
halo,
nitro,
cyano or
a group XR 3 wherein X is oxygen, C(O)m wherein m is 1 or 2, S(O)n wherein n is 0, 1 or 2, or a group NR 4 wherein R 4 is hydrogen or C 1-6 alkyl; and R 3 is hydrogen, C 1-6 alkyl, or a group NR 5 R 6 wherein R 5 and R 6 are independently hydrogen or C 1-6 alkyl; provided that R 3 is not NR 5 R 6 when X is oxygen or S(O)n ;
R 1a and R 1b are independently selected from hydrogen and halo;
R 2 is a group:
Figure USRE037438-20011106-C00038
wherein p, q and r are independently 0, 1 or 2, and R 12 is selected from the group consisting of flouro, hydrogen, and NH 2 ;
in an amount effective to prevent or treat shock states resulting from overproduction of NO by iNOS.
11. The method of claim 10 wherein the condition is selected from the group consisting of septic shock, shock caused by fulminant heptic failure, shock caused by therapy with one or more cytokines and shock caused by therapy with cytokine-inducing agents.
12. A method of treating a condition requiring inhibition of NO synthase, which comprises the step of administering to a mammal a pharmaceutical formulation according to claim 7 in an amount effective to inhibit NO synthase.
13. A method for the prophylaxis or treatment of an auto-immune disease or an inflammatory disease, said method comprising administering an acetamidine derivative of claim 1formula ( 1 ):
Figure USRE037438-20011106-C00039
or a salt thereof, wherein
R 1 is
hydrogen,
a C 1-6 hydrocarbyl group optionally substituted by halo,
halo,
nitro,
cyano or
a group XR 3 wherein X is oxygen, C(O)m wherein m is 1 or 2, S(O)n wherein n is 0, 1 or 2, or a group NR 4 wherein R 4 is hydrogen or C 1-6 alkyl; and R 3 is hydrogen, C 1-6 alkyl, or a group NR 5 R 6 wherein R 5 and R 6 are independently hydrogen or C 1-6 alkyl; provided that R 3 is not NR 5 R 6 when X is oxygen or S(O)n ;
R 1a and R 1b are independently selected from hydrogen and halo;
R 2 is a group:
Figure USRE037438-20011106-C00040
wherein p, q and r are independently 0, 1 or 2, and R 12 is selected from the group consisting of flouro, hydrogen, and NH 2 ;
in an amount effective to prevent or treat an auto-immune disease or an inflammatory disease.
14. A method for the prophylaxis or treatment of a condition resulting from the overproduction of NO by nNOS, said method comprising administering an acetamidine derivative of claim 1formula (I):
Figure USRE037438-20011106-C00041
or a salt thereof, wherein
R 1 is
hydrogen,
a C 1-6 hydrocarbyl group optionally substituted by halo,
halo,
nitro,
cyano or
a group XR 3 wherein X is oxygen, C(O)m wherein m is 1 or 2, S(O)n wherein n is 0, 1 or 2, or a group NR 4 wherein R 4 is hydrogen or C 1-6 alkyl; and R 3 is hydrogen, C 1-6 alkyl, or a group NR 5 R 6 wherein R 5 and R 6 are independently hydrogen or C 1-6 alkyl; provided that R 3 is not NR 5 R 6 when X is oxygen or S(O)n ;
R 1a and R 1b are independently selected from hydrogen and halo;
R 2 is a group:
Figure USRE037438-20011106-C00042
wherein p, q and r are independently 0, 1 or 2, and R 12 is selected from the group consisting of flouro, hydrogen, and NH 2 ;
in an amount effective to prevent or treat conditions resulting from the overproduction of NO by nNOS.
15. A process for the preparation of a compound of formula (1)
Figure USRE037438-20011106-C00043
or a salt thereof, wherein
R1 is
hydrogen,
a C1-6 hydrocarbyl group optionally substituted by halo,
halo,
nitro,
cyano or
a group XR3 wherein X is oxygen, C(O)m wherein m is 1 or 2, S(O)n wherein n is 0, 1 or 2, or a group NR4 wherein R4 is hydrogen or C1-6 alkyl; and R3 is hydrogen, C1-6 alkyl, or a group NR5R6 wherein R5 and R6 are independently hydrogen or C1-6 alkyl, provided that R3 is not NR5R6 when X is oxygen or S(O)n;
R1a and R1b are independently selected from hydrogen and halo;
R2 is a C1-14 hydrocarbyl group the group R2 being optionally substituted by one or more groups independently selected from halo; N3; nitro; CF3; ZR7 wherein Z is oxygen, C(O)m wherein m is 1 or 2, S(O)n wherein n is 0, 1 or 2, or a group NR8 wherein R8 is hydrogen or C1-6 alkyl and R7 is hydrogen, C1-6 alkyl or a group NR9R10 wherein R9 and R10 are independently hydrogen or C1-6 alkyl; or R2 is substituted by a group
Figure USRE037438-20011106-C00044
wherein R11 has a definition the same as R1;
with the proviso that when R1 is a C1-6 alkyl group and R2 is a C1-14 hydrocarbyl substituted by two groups ZR7 wherein one group ZR7 is CO2H, the other group ZR7 is not NH2; N-( 3 -(aminomethyl)benzyl)acetamidine
said process comprising the reaction of an amine of formula (II):
H2N—R2
tert-butyl N-( 3 -aminomethyl)benzyl
or a protected derivative thereof;
with benzylthioacetamidate hydrochloride
Figure USRE037438-20011106-C00045
followed by deprotection if necessary.
16. The acetamidine derivative of claim 5 which is N-( 3 -(aminomethyl)benzyl)acetamidine or a salt thereof.
US09/304,947 1994-12-20 1995-12-20 Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase Expired - Lifetime USRE37438E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/304,947 USRE37438E1 (en) 1994-12-20 1995-12-20 Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9425701.1A GB9425701D0 (en) 1994-12-20 1994-12-20 Enzyme inhibitors
GB9425701 1994-12-20
US09/304,947 USRE37438E1 (en) 1994-12-20 1995-12-20 Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase
US08/860,154 US5866612A (en) 1994-12-20 1995-12-20 Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase
PCT/GB1995/002978 WO1996019440A1 (en) 1994-12-20 1995-12-20 Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/860,154 Reissue US5866612A (en) 1994-12-20 1995-12-20 Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase

Publications (1)

Publication Number Publication Date
USRE37438E1 true USRE37438E1 (en) 2001-11-06

Family

ID=10766226

Family Applications (2)

Application Number Title Priority Date Filing Date
US08/860,154 Ceased US5866612A (en) 1994-12-20 1995-12-20 Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase
US09/304,947 Expired - Lifetime USRE37438E1 (en) 1994-12-20 1995-12-20 Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08/860,154 Ceased US5866612A (en) 1994-12-20 1995-12-20 Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase

Country Status (5)

Country Link
US (2) US5866612A (en)
EP (1) EP0799191A1 (en)
AU (1) AU4268796A (en)
GB (1) GB9425701D0 (en)
WO (1) WO1996019440A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050193412A1 (en) * 2001-07-16 2005-09-01 International Thermal Investments Ltd. Potable water heater and method of using same
US20080114021A1 (en) * 2006-11-09 2008-05-15 University Of Maryland Baltimore Use Of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antimicrobial Agent

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997009982A1 (en) * 1995-09-14 1997-03-20 Nippon Kayaku Kabushiki Kaisha Nitrogen monoxide synthetase inhibitor comprising 2-aminopyridines as active ingredient
AU2978197A (en) * 1996-06-04 1998-01-05 Chugai Seiyaku Kabushiki Kaisha Substituted benzenes having nos inhibitory effects
DE69816790T2 (en) * 1997-01-09 2004-04-22 G.D. Searle & Co., Chicago IMPROVING OPIOID TOLERANCE BY INHIBITING THE INDUCIBLE NITROGEN OXIDE SYNTHASE FOR TREATING PAIN
TW460460B (en) * 1997-11-04 2001-10-21 Chugai Pharmaceutical Co Ltd Heterocyclic compounds having NOS inhibitory activities
CN1171861C (en) * 1998-03-11 2004-10-20 G·D·西尔公司 Halogenated amidino amino acid derivatives useful as nitric oxide synthase inhibitors
GB9810299D0 (en) * 1998-05-15 1998-07-15 Glaxo Group Ltd Use of nitric oxide synthase inhibitors
DE10004928A1 (en) * 2000-02-04 2001-08-09 Solvay Fluor & Derivate Use of perfluorinated two-five carbon carboxylic acid amides as solvent (component) for salt conductors in electrolytes, e.g. for rechargeable batteries
AU2811501A (en) 2000-03-28 2001-10-04 Sumitomo Chemical Company, Limited Amidine compounds and their use as pesticides
US20040235792A1 (en) * 2001-01-20 2004-11-25 Deadman John J Serine protease inhibitors compromising a hydrogen-bond acceptor
US20040235890A1 (en) * 2001-09-10 2004-11-25 Masaharu Komeno Remedies for allergic diseases
JP2006096665A (en) * 2002-10-29 2006-04-13 Ono Pharmaceut Co Ltd Treatment for spinal stenosis
ITTO20040125A1 (en) * 2004-03-01 2004-06-01 Rotta Research Lab NEW HETEROCYCLIC AMIDINS INHIBITIVE THE PRODUCTION OF NITROGEN OXIDE (NO) FOR ANTI-INFLAMMATORY AND ANALGESIC ACTIVITY
CN114957042B (en) * 2022-07-01 2024-06-07 苏州莱克施德药业有限公司 Synthesis process of 2, 2-trifluoroacetamidine

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1183135A (en) 1967-04-13 1970-03-04 Ciba Ltd 2,4-Benzodiazepines, process for their manufacture and Compositions containing them
DE2020155A1 (en) 1970-04-24 1971-11-04 Ishihara Sangyo Kaisha Germicidal amidine derivs
DE2300221A1 (en) 1973-01-04 1974-07-18 Agfa Gevaert Ag PROCESS FOR THE PREPARATION OF 3ANILINO-PYRAZOLONES- (5)
DE2601137A1 (en) 1975-01-15 1976-07-22 Merck & Co Inc SUBSTITUTED PERHALOGENALKYLAMIDINES AND HEART STIMULANTIES
DE2557651A1 (en) 1975-12-20 1977-06-23 Basf Ag Fungicidal (N)-aryl-(2,2)-dihalo-acetamidine derivs. prepn. - by reacting (N)-aryl-(N')-acyl-trihalo-acetaldehyde aminal derivs.with base
WO1993013055A1 (en) 1991-12-24 1993-07-08 The Wellcome Foundation Limited Amidino derivatives and their use as nitric oxide synthase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB861526A (en) * 1958-02-07 1961-02-22 Ici Ltd New pharmaceutical compositions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1183135A (en) 1967-04-13 1970-03-04 Ciba Ltd 2,4-Benzodiazepines, process for their manufacture and Compositions containing them
DE2020155A1 (en) 1970-04-24 1971-11-04 Ishihara Sangyo Kaisha Germicidal amidine derivs
DE2300221A1 (en) 1973-01-04 1974-07-18 Agfa Gevaert Ag PROCESS FOR THE PREPARATION OF 3ANILINO-PYRAZOLONES- (5)
DE2601137A1 (en) 1975-01-15 1976-07-22 Merck & Co Inc SUBSTITUTED PERHALOGENALKYLAMIDINES AND HEART STIMULANTIES
DE2557651A1 (en) 1975-12-20 1977-06-23 Basf Ag Fungicidal (N)-aryl-(2,2)-dihalo-acetamidine derivs. prepn. - by reacting (N)-aryl-(N')-acyl-trihalo-acetaldehyde aminal derivs.with base
WO1993013055A1 (en) 1991-12-24 1993-07-08 The Wellcome Foundation Limited Amidino derivatives and their use as nitric oxide synthase inhibitors

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
Bolhoffer, W. A., et al. 2-Mercaptoacetamidines as gastric antisecretory agents, Journal of Medicinal Chemistry vol. 22, No. 3 (1979) Washington US, pp. 295-301.
Database Crossfire, Beilstein Informationssysteme GmbH, Frankfurt DE, see BRN 113878 Et J. Heterocycl. Chem., vol. 12 (1975) p. 407.
Database Crossfire, Beilstein Informationssysteme GmbH, Frankfurt DE, see BRN 2346409 Et Chem. Ber., vol. 93 (1960) pp. 2230-2238.
Database Crossfire, Beilstein Informationssysteme GmbH, Frankfurt DE, see BRN 2717900 Et GB ,A, 861 526 (1958).
Database Crossfire, Beilstein Informationssysteme GmbH, Frankfurt DE, see BRN 3278146 Et Recl. Trav. Chim. Pays-Bas, vol. 70 (1951) p. 638, 641.
Database Crossfire, Beilstein Informationssysteme GmbH, Frankfurt DE, see BRN 3777937 Et Justus Liebigs Ann. Chem., vol. 575 (1952) p. 90ff.
Database Crossfire, Beilstein Informationssysteme GmbH, Frankfurt DE, see BRN 394415 Et Can. J. Chem., vol. 39 (1961) pp. 761-764.
Database Crossfire, Beilstein Informationssysteme GmbH, Frankfurt DE, see BRN 473624 Et J. Indian Chem. Soc., vol. 39 (1962) pp. 208-210.
Database Crossfire, Beilstein Informationssysteme GmbH, Frankfurt DE, see BRN 6423899 Et Gazz. Chim. Ital., vol. 113, No. 1-2 (1983) pp. 77-82.
Database Crossfire, Beilstein Informationssysteme GmbH, Frankfurt DE, see BRN 746863 Et Bull Chem Soc. Jpn, vol. 45 (1972) pp. 2010-2015.
Database Crossfire, Beilstein Informationssysteme GmbH, Frankfurt, DE, see BRN 1790943 Et J. Chem. Soc. (1947) p. 730.
Database Crossfire, Beilstein Informationssysteme GmbH, Frankfurt, DE, see BRN 7088281, see BRN 7089080 Et Farmaco Ed. Sci., vol. 43, No. 1 (1988) pp. 102-112.
J. Oszczapowicz, et al, Chemical Abstracts, vol. 102, No. 10, Mar. 11, 1985 Columbus, Ohio, US; Et J. Chromatogr., vol. 315 (1984) pp. 95-100.
Journal of Medicinal Chemistry, vol. 37, No. 23, Nov. (1994) Washington US, pp. 3886-3888.
Keir, W. F., et al. Amidinoacetamides in the synthesis of pyrimidines, imidazoles and purines, Journal of the Chemical Society, Perkin Transactions 1 (1976) Letchworth GB, pp. 1847-1852.
Parulkar, A. P., et al., N-Heteroaralkyl substituted . alpha.-amidinium thiolsulfates, Journal of Heterocyclic Chemistry, vol. 3, No. 4 (1996) Provo US, pp. 472-475.
Saari, W.S., et al, Trichloroacetamidines, a new class of positive inotropic agents, Journal of Medicinal Chemistry, vol. 21, No. 12 (1978) Washington U.S., pp. 1283-1290.
T. T. Conway, et al., Chemical Abstracts, vol. 68, no. 21, May 20, 1968, Columbus, Ohio US; Et J. Pharm. Sci., vol. 57, No. 3 (1968) pp. 455-459.

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050193412A1 (en) * 2001-07-16 2005-09-01 International Thermal Investments Ltd. Potable water heater and method of using same
US20080114021A1 (en) * 2006-11-09 2008-05-15 University Of Maryland Baltimore Use Of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antimicrobial Agent
US20110218239A1 (en) * 2006-11-09 2011-09-08 University Of Maryland Baltimore Use of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antiviral Agent
US8957108B2 (en) 2006-11-09 2015-02-17 University Of Maryland, Baltimore Use of 5,6-dimethylxanthenone-4-acetic acid as an antiviral agent

Also Published As

Publication number Publication date
AU4268796A (en) 1996-07-10
EP0799191A1 (en) 1997-10-08
GB9425701D0 (en) 1995-02-22
US5866612A (en) 1999-02-02
WO1996019440A1 (en) 1996-06-27

Similar Documents

Publication Publication Date Title
USRE37438E1 (en) Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase
AU702487B2 (en) Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists
US11046644B2 (en) Sulfur derivatives as chemokine receptor modulators
US5874472A (en) Aminoacid derivatives as no synthase inhibitors
KR19990082622A (en) IL-8 receptor antagonist
SK94196A3 (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them, manufacturing process thereof and their use
AU720615B2 (en) Bis-sulfonomides hydroxamic acids as MMP inhibitors
EP0749418B1 (en) L-n6 -(1-iminoethyl)lysine derivatives useful as nitric oxide synthase inhibitors
WO1995009619A2 (en) Substituted urea and isothiourea derivatives as no synthase inhibitors
EP3038612B1 (en) Cyclic vinylogous amides as bromodomain inhibitors
EP0934068A1 (en) Compounds and methods
EP1200419B1 (en) Aminothiazole derivatives and their use as crf receptor ligands
US6645968B2 (en) Potassium channel openers
JPH11500711A (en) Acetamidine derivatives and their use as NO synthase inhibitors
AU3877899A (en) Substituted beta-amino acid inhibitors of methionine aminopeptidase-2
US6090846A (en) Substituted urea and isothiourea derivatives as no synthase inhibitors
US6225305B1 (en) Substituted urea and isothiorea derivatives as no synthase inhibitors
US6297276B1 (en) Substituted urea and isothiourea derivatives as no synthase inhibitors
CA2184691C (en) L-n6-(1-iminoethyl)lysine derivatives useful as nitric oxide synthase inhibitors
HRP930669A2 (en) Transdermal terapheutic system with physostigmin as an active substance

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12